WO2014184596A2 - SMALL PEPTIDE INHIBITORS OF β-AMYLOID TOXICITY - Google Patents
SMALL PEPTIDE INHIBITORS OF β-AMYLOID TOXICITY Download PDFInfo
- Publication number
- WO2014184596A2 WO2014184596A2 PCT/HU2014/000042 HU2014000042W WO2014184596A2 WO 2014184596 A2 WO2014184596 A2 WO 2014184596A2 HU 2014000042 W HU2014000042 W HU 2014000042W WO 2014184596 A2 WO2014184596 A2 WO 2014184596A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amide
- absent
- ala
- pro
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 136
- 239000003112 inhibitor Substances 0.000 title description 5
- 230000006974 Aβ toxicity Effects 0.000 title description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 90
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 43
- 239000000816 peptidomimetic Substances 0.000 claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 12
- 230000004224 protection Effects 0.000 claims abstract description 9
- 238000011321 prophylaxis Methods 0.000 claims abstract description 8
- 230000001627 detrimental effect Effects 0.000 claims abstract description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 24
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 21
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims description 18
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 18
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 17
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 14
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 12
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 12
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims description 8
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 206010002022 amyloidosis Diseases 0.000 claims description 8
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 8
- JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 claims description 8
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 claims description 8
- 229950001139 timonacic Drugs 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims description 4
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 2
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- 208000015756 familial Alzheimer disease Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 abstract description 33
- 238000004220 aggregation Methods 0.000 abstract description 33
- 108090000623 proteins and genes Proteins 0.000 abstract description 33
- 102000004169 proteins and genes Human genes 0.000 abstract description 33
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 8
- 238000009825 accumulation Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 229930189370 prionoid Natural products 0.000 abstract description 7
- 206010029350 Neurotoxicity Diseases 0.000 abstract description 5
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract description 5
- 231100000228 neurotoxicity Toxicity 0.000 abstract description 5
- 230000007135 neurotoxicity Effects 0.000 abstract description 5
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 230000007505 plaque formation Effects 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 23
- 210000002569 neuron Anatomy 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 22
- 239000000902 placebo Substances 0.000 description 22
- 229940068196 placebo Drugs 0.000 description 22
- 102000013498 tau Proteins Human genes 0.000 description 22
- 108010026424 tau Proteins Proteins 0.000 description 22
- 229920005989 resin Polymers 0.000 description 21
- 239000011347 resin Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 231100000331 toxic Toxicity 0.000 description 16
- 230000002588 toxic effect Effects 0.000 description 16
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 15
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 13
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 11
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 11
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 9
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- 102000029797 Prion Human genes 0.000 description 7
- 108091000054 Prion Proteins 0.000 description 7
- 230000035508 accumulation Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000001320 hippocampus Anatomy 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000001049 Amyloid Human genes 0.000 description 6
- 108010094108 Amyloid Proteins 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 6
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 6
- 229920001367 Merrifield resin Polymers 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000012347 Morris Water Maze Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000010150 least significant difference test Methods 0.000 description 6
- 230000027928 long-term synaptic potentiation Effects 0.000 description 6
- 230000000324 neuroprotective effect Effects 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 5
- -1 4-fluoro-Pro Chemical compound 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 108010036933 Presenilin-1 Proteins 0.000 description 5
- 102000012412 Presenilin-1 Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000010304 firing Methods 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 4
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 4
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 4
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 4
- 108050003242 Kelch-like protein 41 Proteins 0.000 description 4
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 4
- 229960002327 chloral hydrate Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000006764 neuronal dysfunction Effects 0.000 description 4
- 230000002887 neurotoxic effect Effects 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- NPKKRSHVJIQBKU-UHFFFAOYSA-N ornogenin Natural products CC(OC(=O)C=Cc1ccccc1)C2(O)CCC3(O)C4(O)CC=C5CC(O)CCC5(C)C4CC(OC(=O)C=Cc6ccccc6)C23C NPKKRSHVJIQBKU-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 3
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000007792 alzheimer disease pathology Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003941 amyloidogenesis Effects 0.000 description 3
- 230000003942 amyloidogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000002212 electronic circular dichroism spectrum Methods 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000009878 intermolecular interaction Effects 0.000 description 3
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 231100000189 neurotoxic Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- SSSRLHJWMBEUAF-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]acetamide Chemical compound NC(=O)CC1=CC=C(CO)C=C1 SSSRLHJWMBEUAF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- 229930182847 D-glutamic acid Natural products 0.000 description 2
- 229930182820 D-proline Natural products 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000500121 Mirax Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 230000008335 axon cargo transport Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000002519 electronic circular dichroism spectroscopy Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000006951 hyperphosphorylation Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100039010 Caenorhabditis elegans dis-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241000201966 Goura Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241001562042 Physa Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- DOIXGGGORNAJAT-UHFFFAOYSA-M [NH4+].[Ni+].[O-]S([O-])(=O)=O Chemical compound [NH4+].[Ni+].[O-]S([O-])(=O)=O DOIXGGGORNAJAT-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000005311 autocorrelation function Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- BPHHNXJPFPEJOF-UHFFFAOYSA-J chembl296966 Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3OC)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)O)OC)=CC=C21 BPHHNXJPFPEJOF-UHFFFAOYSA-J 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000003503 early effect Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005279 excitation period Effects 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000035557 fibrillogenesis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- VHGXRGXCDVQIKS-KRWDZBQOSA-N methyl (2s)-3-(4-methylphenyl)sulfonyloxy-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C([C@@H](C(=O)OC)NC(=O)OCC=1C=CC=CC=1)OS(=O)(=O)C1=CC=C(C)C=C1 VHGXRGXCDVQIKS-KRWDZBQOSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000007645 synaptic failure Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
- C07K5/06121—Asp- or Asn-amino acid the second amino acid being aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to peptides and peptidomimetics useful for reducing the neurotoxicity of amyloid peptide aggregates or prion-like (prionoid) protein aggregates, the invention further relates to pharmaceutical compositions containing said peptides and/or peptidomimetics, to the use of said peptides and/or peptidomimetics in the manufacture of medicines useful for the prophylaxis or treatment of diseases that can be cured by protection against the detrimental effect of ⁇ -peptides /abnormal ⁇ aggregation leading to amyloid plaque formation, and it relates to the use of said peptides and/or peptidomimetics in the prophylaxis or treatment of the above mentioned diseases.
- the invention aimed at developing treatments of neurodegenerative diseases, particularly Alzheimer' s disease (AD) , during which accumulation of misfolded and/or aggregated proteins occurs.
- AD Alzheimer' s disease
- AD Alzheimer's disease
- PD Parkinson's, Disease
- Ac acetyl
- ACN acetonitrile
- APP amyloid precursor protein
- Aib 2-aminoisobutyric acid; ala, D-alanine; pro, D-proline; glu, D-glutamic acid; asp, D-aspartic acid; Glp, L- pyroglutamic acid; Sar, sarcosin; Pip, L-pipecolic acid; sue, succinyl; GABA, gamma-aminobutyric acid; Abu, 2-aminobutyric acid; Tic, Tetrahydro-isoquinoline-3-carboxylic acid.
- chiral amino acids can have either L- or D-configuration . If an amino acid is mentioned in the present description both L- or D- configuration has to be understood, unless the configuration is specified.
- AD the most common of senile dementias, is a global health crisis with devastating effects on individuals, families and societies. There is an urgent need to develop efficient and relatively cheap treatments for the early stage of the disease and/or prevention strategies to replace currently available medications which only reduce the symptoms and the progression of the disease but does not solve the underlying problem.
- AD Alzheimers Dis 3(l):75-80, 2001.
- amyloid plaques comprising deposits of ⁇ and neurofibrillary tangles consisting of tau, a microtubule-associated protein (Selkoe, J Alzheimers Dis 3(l):75-80, 2001).
- ⁇ aggregates are mainly ⁇ -sheets with all the hallmark characteristics of amyloid fibrils, including a cross-beta diffraction pattern and characteristic staining by the dyes Congo Red and thioflavin T (Eanes and Glenner, J Histochem Cytochem 16 (11) : 673-7, 1968; LeVine, Protein Sci 2(3):404-10, 1993; Sipe and Cohen, J Struct Biol 130 (2-3) : 88-98, 2000) .
- Tau filaments adopt various morphologies, including paired helical filaments, which are ⁇ - sheet rich fibrils that appear as twisted structures under electron microscopy, and straight filaments, which lack the twisted morphology (Goedert et al., Curr Opin Neurobiol 8(5): 619-32, Review, 1998). Tau filaments bind the dye thioflavine S (ThS) and yield fluorescent signal and have a cross-beta diffraction pattern (Berriman et al., Proc Natl Acad Sci U.S.A. 100 (15) :9034-8, 2003; Friedhoff et al., Biochemistry 37 (28) :10223-30, 1998) .
- Thioflavine S Thioflavine S
- AD is characterized by the formation of extracellular amyloid plaques, cerebrovascular amyloid deposits, intracellular neurofibrillary tangles (NT) and neuronal loss in the brain. While NTs mainly consist of the microtubule-associated protein tau (Selkoe, Physiol Rev 81: 741-766, 2001), the amyloid plaques contain large amounts of amyloid beta ( ⁇ ) peptides (a length of 39-43 amino acids) , which are produced by the proteolytic cleavage of a much longer amyloid precursor protein (APP) in neurons and other cells throughout life (Haass et al. Nature 359: 322-325, 1992).
- ⁇ amyloid beta
- dysregulation of APP processing is the key initiating event in AD pathogenesis, subsequently leading to increased levels and aggregation of extracellular ⁇ ( ⁇ ) , specifically ⁇ 1-42 (that is, the 42 amino acid length version of ⁇ ) .
- ⁇ oligomerization and/or fibrillogenesis trigger a cascade of cellular and molecular events, including disturbed axonal transport, development of synaptic failure, neuronal loss, reduction in neurotransmitter levels, all of which result in defects in cognition, synaptic plasticity and in development of tau pathology (Hardy and Higgins, Science 256: 184-185, 1992) .
- GPCRs G protein coupled receptors
- ⁇ has been widely detected in neuronal cells and primary human neurons, and shown to have a broad range of interaction with proteins and subcellular organelles.
- Studies in several mouse models of AD with intraneuronal ⁇ -expression and accumulation (Casas et al Am J Pathol 165: 1289-1300, 2004; Billings Neuron 45: 675-688, 2005; Tomiyama J Neurosci 30: 4845-4856, 2010; Abramowski et al. J Neurosci 32: 1273-1283, 2011) have proven that ⁇ causes the onset of early AD cognitive deficits in transgenic mice.
- AD microtubular protein tau
- Tau is an important protein in AD pathology: the Braak staging of the disease (Braak and Braak Neurobiol Aging 16(3):271-8, 1995) is based on the localization of tau deposits in brain structures. Similarly to ⁇ , hyperphosphorylated tau can also form toxic intracellular aggregates. As a consequence of formation of tau deposits, the microtubular system collapse and the axonal transport fails (Iqbal et al. Acta Neuropathol 109 (1) : 25-312, 2009; Takashima Curr Alzheimer Res 5(6): 591-8, 2008), which results in neuronal dysfunction and cell death.
- AD is regarded as a special form of tauopathies with primacy of ⁇ , that is accumulation of ⁇ , and ⁇ starts the pathological processes of AD. Both species of ⁇ trigger tau-hyperphosphorylation, however, tau protein is also required for ⁇ -induced neuronal dysfunction (Shipton et al. J Neurosci 31: 1688-1692, 2011).
- AD drug research has used the amyloid cascade hypothesis.
- Putative neuroprotective agents were tried in the pipeline that selectively block ⁇ aggregation and/or enhance clearance of ⁇ peptides.
- several other approaches have been developed to reduce neuronal loss (neuroprotection) caused by ⁇ .
- One of them is targeting the risk factors in an attempt to neutralize or inhibit their action. In the presence of ⁇ - and ⁇ -secretase inhibitors, ⁇ 1-42 is not formed.
- ⁇ immunization was also considered as another promising approach for AD therapy.
- clinical studies revealed a strong brain inflammatory response in immunized patients (Munch and Robinson, J Neural Transm 109(708): 1081-1087, 2002).
- Dramatic advances in understanding the neurobiology of AD have revealed a new direction for drug development, e.g. the identification of specific aggregation states of ⁇ (for a review, see Broersen et al., Alz.
- amyloid formation is a nucleation-polymerization reaction, that is characterized by an initial lag phase dominated by monomeric (M) species, followed by the formation of low-molecular weight (LMW) soluble oligomers (dimer, trimer and ⁇ 8-mers) .
- LMW low-molecular weight
- ⁇ -sheet rich oligomeric intermediates are referred to as prefibrillar aggregates, which disappear upon fibril formation.
- Congo red and Thioflavin-T are less stable than mature fibrils.
- Amyloid fibrils are insoluble, ⁇ -sheet rich structures that contain 2-6 protofilament subunits.
- the key pathogenic event in the onset of AD is believed to be the formation of soluble forms of neurotoxic/synaptotoxic ⁇ -amyloid peptides (A ⁇ 42 oligomers and protofibrils), which are intrinsically disordered proteins that possess many metastabil conformational states, thereby able to interact with several proteins of the neural cells (Tompa FEBS J 276 (19) : 5406-15, 2009; Broersen et al. Alzheimer's Res & Therapy 2(4): 12-14, 2010) . Understanding the precise chemical nature of the toxic ⁇ oligomeric species is an important goal that may ultimately help the design of specific molecules, which will be able to correct a particular cellular dysfunction by restoring normal signal transduction and the ability of nerve cells to communicate .
- W neurotoxic/synaptotoxic ⁇
- ⁇ may be directly toxic to neuronal cells and synapses.
- the intrinsically disordered (ID) structures of ⁇ represent transient intermediates in the aggregation cascade in patient brains.
- the pathology of AD, the Braak stages (Braak H. and Braak E. Neurobiol. Aging 16:271-278, 1995) also support the idea that AD spreads from neuron to neuron. It is almost forgotten that at the beginning of eighties-nineties and AD- research, the disease was suspected of being a prion disease (Prusiner Biochemistry 23(25): 5898-906, 1984; Gajdusek Mol Neurobiol 8(1): 1-13.1994).
- cerebral ⁇ -amyloidosis can be exogenously induced by exposure to dilute brain extracts containing aggregated ⁇ seeds (seeding-nucleation model) . It has been shown recently that pure ⁇ injections into the brain may induce plaques throughout the whole brain within 5 to 6 months (Stohr et al. Proc Natl Acad Sci U S A. 27, 11025-30, 2012) . If the peptides were injected to one hemisphere, plaque formation started in both halves of the brain. The amyloid- inducing agent probably is ⁇ itself (Auer et al.
- Infectious prions and prionoids can be prepared by protein misfolding cyclic amplification (PMCA) (Soto et al, TINS 25: 390394, 2002, Saa et al. J Biol Chem 281: ' 35245-35252, 2006; Murayama et al. Neurosci Lett 413: 270-273, 2007; Soto and Matteri Trend Mol Med 17: 14-24, 2011; Gonzalez- Montalban et al. PLoS Pathog 7:el001277, 2011; Moreno-Gonzalez and Soto Semin Cell Dev Biol 22: 482-487, 2011).
- PMCA protein misfolding cyclic amplification
- a co-factor might be an essential element of the infectious agent.
- a co-factor might act as an essential catalyst for prion/prionoid conversion, help to stabilize the hypertoxic conformation and might increase the biological stability of prions/prionoids (Soto TIBS 36(3):151-8, 2010).
- a novel compound for the prophylaxis and treatment of AD should prevent the formation of toxic ⁇ oligomers and the conformational change into infectious prionoid species.
- Such compound preferably also prevents any interaction between toxic extra- or intracellular ⁇ and neuronal cell membranes, membrane proteins and intraneuronal as well as molecular organelles. If these interactions are hindered, ⁇ cannot initiate tau-pathology, the release of lysosomal enzymes and apoptotic cell death.
- the problem according the present invention is that an effective means is missing to inhibit ⁇ aggregation to toxic oligomers in order to prevent or treat diseases that are the consequence of ⁇ aggregation, that is that can be cured by protection against the detrimental effect of ⁇ -peptides.
- the object of the present invention is to provide compounds that can effectively inhibit ⁇ aggregation to toxic oligomers and inititate aggregation to big, non-toxic assemblies.
- These compounds will be useful in the prophylaxis and treatment of diseases associated with ⁇ aggregation, wherein such diseases include, without limitation, neurodegenerative diseases, like AD and Parkinson's disease, Down syndrome, type II diabetes, amyloidosis etc.
- the present invention provides a novel group of short peptides and peptidomimetics. These peptides - among other useful effects - inhibit ⁇ aggregation. Briefly, the present invention relates to the following
- X is absent or represents: acetyl, propionyl, succinyl group
- Al is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, oi-methyl-Ala, Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, succinyl, Pro, acetyl, 2-amino-adipoic acid, propionyl group;
- A2 is absent or represents: Pro, Tic, thiaproline, a-methyl-
- GABA propionyl group
- A3 is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, ⁇ -methyl-Ala, Abu, norvaline, Asp, Glu, Glp, acetyl, succinyl, GABA, propionyl group;
- A4 is absent or represents: Pro, Tic, thiaproline, a-methyl-
- A5 represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala,
- Y is absent or represents: amide, N-methylamide, or N, N- dimethyl-amide;
- A2 is absent than Al is also absent and if A3 is absent than Al and A2 are also absent, and if A4 is absent than Al, A2 and A3 are also absent;
- the present invention relates to peptides containing from 1 to 5 amino acid moieties, where - apart from the naturally occuring amino acids - also some artificial amino acids and peptide chain ends are also present.
- Al, A2, A3, A4 and A5 are selected in such a way that the resulting peptide or peptidomimetic bind to the natural ⁇ , thereby modulating its aggregation properties and inhibits its neurotoxicity via a conformational change.
- the present invention relates preferably to peptides and peptidomimetics listed in Table 2. (see below)
- the present invention relates more preferably to peptides and peptidomimetics of the following formulas: EPP-amide (SEQ ID NO 13),
- EPAPA SEQ ID NO 28
- the invention relates to pharmaceutical
- peptidomimetic of the general formula (I) its salt and ester and at least one pharmaceutically acceptable additive.
- this additive is a matrix ensuring controlled release .
- the invention relates preferably to pharmaceutical
- EPPPA (SEQ ID NO 29)
- apapq (SEQ ID NO 46)
- apapn (SEQ ID NO 48)
- the invention also relates to the use of peptides and/or peptidomimetics according to general formula (I) and their pharmaceutically acceptable salt and ester in the manufacture of a pharmaceutical preparation suitable for the prophylaxis and/or treatment of diseases selected from the group of neurodegenerative diseases associated with ⁇ aggregation, Down syndrome, type II diabetes, and amyloidosis.
- Fig. 1 shows the TEM images of oligomeric and fibrillar structures of ⁇ 1-42 prepared from iso- ⁇ 1-42 (75 ⁇ ) at 0 min A) , 4 h B) , and 24 h C) in the absence and presence
- Fig. 2 shows the effect of the apape pentapeptide on the size distribution of the amyloid aggregates (50 ⁇ ) .
- dH hydrodynamical diameter
- CG7 control peptide Cys-(Gly)7.
- the apape pentapeptide (1:5 molar ratios) facilitated the formation of large agregates of beta amyloid, which formed already after 4 h of incubation, whereas the control peptide did not show a similar effect. After 24 h the presence of fibrillar aggregates could be observed in both samples.
- Fig. 3 displays the ECD spectra recorded over a 168 h period for ⁇ 1-42, apape-NH2 and a 1:5 molar ratio mixture of ⁇ 1-42 and apape-NH2.
- Fig. 4 shows the backbone-fitted representatives of the indicated peptides obtained by cluster analysis. The ribbon is always fitted to the representative of the largest cluster.
- Fig. 5 indicates the time-dependence of the signal intensity of apape in the presence of ⁇ 1-42 in 1H NMR spectra (a). Concentrations were 250 ⁇ for iso ⁇ 1-42 and 1.9 mM for apape. After 24 hours, the bound fraction of apape was 3.5 % (diamond). In this case 66.5 ⁇ apape bound to ⁇ 1-42, which assumes 1:4 binding, respectively.
- the control signal intensity of apape without ⁇ 1-42 was marked by square, (b) : After 1 week, the final value of the bound fraction of apape was 9 % (diamond). In this case, one apape can bind to one ⁇ 1-42.
- the control signal intensity of apape without ⁇ 1-42 was 100 ⁇ 0.3 % during the examined period (square) .
- (c) Scaled 1H NMR methyl signals of the free apape sample (dark grey) and apape + ⁇ 1-42 after 24 hours incubation (light grey) .
- (d) Signal assignment of apape;
- (e) part of 1H NMR spectrum of apape. Shifting of the N-terminal Ala protons was observed upon addition of iso ⁇ 1-42. Lower spectrum is the control apape spectrum and upper spectrum is after 24 hours addition of iso ⁇ 1-42.
- Fig. 6 demonstrates that the peptide pape in vitro protects against the LTP impairment caused by ⁇ 1-42 in mouse hippocampal slices.
- LTP was induced by theta burst stimulation (TBS) , and was followed for 75 min (A) .
- Panel B shows the mean for field excitatory postsynaptic potential (fEPSP) amplitudes 85-90 min after TBS. * p ⁇ 0.05 versus control; one-way ANOVA followed by Dunnett's test.
- Fig. 7 shows the effect of intraperitonially administered apape and pentaglycine (GGGGG) on the NMDA response-enhancing effect of ⁇ 1-42 (the first grey bar) .
- Fig. 8 depicts the neuroprotective effect of apape in the Morris water maze task in rats. Bar graphs show the mean ⁇ SEM. Latencies to reach the platform in second on each of five days. Animals were divided into the following four groups: hydrogen carbonate buffer (HCBS) treated, physiological saline injected control (white); HCBS treated, apape (10 mg/bwkg, i.p.) injected (light grey) ; injected with oligomeric ⁇ 1-42 (75 ⁇ , aggregated for 136 h, i.e.
- Fig. 9 shows the neuroprotective effect of apape in the Morris water maze task in APP x PS1 mice. Bar graphs show the mean ⁇ SEM. latencies to reach the platform in second on each of five days. Animals were divided into the following four groups: placebo injected, wild group (white) ; apape injected wild group (light grey); apape injected APPxPSl mice (black); placebo injected APPxPSl mice (dark grey) .
- Fig. 10 shows the neuroprotective effect of apape during the first swimming in the Morris water maze task in APP x PS1 mice. Bar graphs show the mean ⁇ SEM. latencies to reach the platform in second on each of five days.
- Fig. 11 displays tau histology in 50 micrometer thick hippocampal sections of female APPxPSl transgenic mouse strain.
- the vertical axis shows the mean of the number of tau immune positive cells in wild-placebo injected (white) ; APPxPSl transgenic-placebo administered (light grey) ; apape injected wild (black) ; and the apape injected transgenic (dark grey) animals.
- the APPxPSl transgenic-placebo injected group was expressed as mean ⁇ SEM.
- X acyl group
- Y organic functional group
- Al, A2, A3, A4 and A5 are amino acids (coded and non coded, L or D) or acyl group
- Peptide structures of the present invention were designed on the basis of computer performed analysis of the common binding sequences of ⁇ 1-42 binding proteins (Verdier et al. J. Neurochem. 94, 617-28, 2005). (Table 4).
- the common ⁇ -binding sequences of these proteins revealed by proteomic methods are very similar, containing mainly hydrophobic amino acids, proline and airtinodicarboxylic acids.
- proline residues were incorporated in different part of the molecule since it is known to have greater ⁇ -breaking potential than the other proteinogenic amino acids (Chou and Fasman, Annu Rev Biochem 47: 251-276, 1978).
- the soluble forms of neurotoxic/synaptotoxic ⁇ -amyloid peptides have no definite conformations, only some secondary structural elements (e.g. ⁇ - sheet parts) .
- the ⁇ -peptides belong to the family of intrinsically disordered proteins (IDP) . These proteins interact non-specifically with a big number of important cellular proteins causing neuronal dysfunction.
- IDP intrinsically disordered proteins
- the new class of compounds acts as ⁇ -amyloid structure modifying agents. They bind to the soluble, toxic ⁇ oligomers and protofibrils via a salt bridge and apolar interaction (s) , and convert them to nontoxic conformation. Afterwards, these peptides initiate aggregation to big, non-toxic ⁇ -aggregates . Simultaneously, the novel class of compounds stimulates the formation of dendrites and improves communication between the neurons.
- the present invention relates to peptides and peptidomimetics of the following formula:
- X acyl group
- Y organic functional group
- A1-A5 are amino acids (coded and non coded, R or S) or acyl group (see Table 1) .
- the present invention also relates to amino acid sequences, which are sequentially analogous to the described sequences and the biological activity of which is also analogous when
- modifications may be based on the relative similarity of the amino acid side chains, for example on similarities in size, charge, hydrophobicity, hydrophilicity, etc.
- the aim of such changes may be to increase the stability of the peptide against enzymatic decomposition or to improve certain pharmacokinetic parameters .
- the scope of protection of the present invention also includes peptides, in which elements ensuring detectability (e.g.
- the scope of protection of the present invention also includes peptides, which contain a few further amino acids at their N-terminal, C-terminal, or both ends, if these further amino acids do not have a significant influence on the
- the aim of such further amino acids positioned at the ends may be to facilitate immobilisation, ensure the possibility of linking to other reagents, influence solubility, absorption and other
- the present invention also relates to the pharmaceutically acceptable salts of the peptides with general formula (I) according to the invention.
- salts which, during contact with human or animal tissues, do not result in an unnecessary degree of toxicity, irritation, allergic symptoms or similar phenomena.
- acid addition salts the following are mentioned: acetate, citrate, aspartate, benzoate, benzene sulphonate, butyrate, digluconate, hemisulphate, fumarate, hydrochloride,
- salts based on the following are mentioned: alkali metals and alkaline earth metals (lithium, potassium, sodium, calcium, magnesium, aluminium) , quaternary ammonium salts, amine cations (methylamine, ethylamine, diethylamine, etc. ) .
- the peptides according to the invention can be used in any convenient manner.
- the peptides according to the invention can be used in any convenient manner.
- Such preparations may be pharmaceutical preparations combined for example with matrices ensuring controlled active substance release, widely known by a person skilled in the art.
- matrices ensuring controlled active substance release are polymers, which, when entering the appropriate tissue (e.g. blood plasma) decompose for example in the course of enzymatic or acid-base hydrolysis (e.g. polylactide, polyglycolide) .
- the pharmaceutical preparations according to the invention can be entered in the organism via parenteral
- compositions may be aqueous or non-aqueous solutions, dispersions, suspensions, emulsions, or solid (e.g. powdered) preparations, which can be transformed into one of the above fluids directly before use.
- suitable vehicles, carriers, diluents or solvents may be for example water, ethanol, different polyols (e.g. glycerine, propylene glycol, polyethylene glycols and similar substances) , carboxymethyl cellulose, different (vegetable) oils, organic esters, and mixtures of all these substances.
- preparations according to the invention include for example tablets, powders, granules, suppositories, injections, syrups, etc .
- the administered dose depends on the type of the given disease, the patient's sex, age, weight, and on the severity of the disease.
- the favourable daily dose may vary for example between 0.01 mg and 1 g, in the case of parenteral administration (e.g. a preparation
- the favourable daily dose may vary for example between 0.001 mg and 100 mg in respect of the active agent.
- the pharmaceutical preparations can also be used in state-of-the-art liposomes or microcapsules.
- the peptides according to the invention can also be entered in the target organism by state-of-the-art means of gene therapy.
- the peptides according to the invention can be used first of all in the medical treatment of diseases, in the case of which the inhibition of aggregation of ⁇ -amyloid to toxic species is beneficial, wherein the target ⁇ -amyloid peptide comprises a ⁇ - sheet sequence susceptible to further aggregation up to
- the present invention also relates to the use of peptides in the manufacture of drugs for the treatment of such diseases.
- diseases are first of all certain
- Alzheimer's and Parkinson's disease a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention.
- 'aggregation' means the association of peptide moieties, whether the resulting structure is regular or irregular, stable or unstable or with ordered or disordered native states. Such association can occur through intermolecular interactions, hydrophobic interactions, hydrogen bonds, van der aals forces, ionic bonds or any force or substance that can result in the collection or association together of two or more peptides or peptide regions.
- aggregation encompasses, for example, fibrillation, or the formation of fibrils.
- amyloid describes various types of protein aggregations that share specific traits when examined microscopically.
- the name amyloid comes from the early mistaken identification of the substance as starch (amylum in Latin) , based on crude iodine- staining techniques.
- Amyloid is typically identified by a change in the fluorescence intensity of planar aromatic dyes such as Thioflavin T or Congo Red. This is generally attributed to the environmental change as these dyes intercalate between beta-strands.
- the deposits are characterized by the abnormal folding of amyloidogenic protein from a normal secondary structure (often an a-helix, but can also be a random coil) into a pathological ⁇ -sheet structure, which permits aggregation into insoluble fibrils.
- amyloid fibrils are made up of a helical configuration of two protofilaments . These deposits are characteristically resistant to protease digestion. Amyloid polymerization is generally sequence-sensitive, that is, causing mutations in the sequence can prevent self-assembly, especially if the mutation is a beta-sheet breaker, such as proline. For example, humans produce an amyloidogenic peptide associated with type II diabetes, but in rodentia, a proline is substituted in a critical location and amyloidogenesis does not occur. Approximately 25 different proteins are known that can form amyloid in humans.
- 'amyloidosis' refers to a disease or disorder associated with abnormal protein folding into amyloid or amyloid-like fibrillar deposits in which the abnormally folded proteins in the deposits have a characteristic pathological beta-sheet structure.
- ⁇ -amyloid peptide', 'amyloid ⁇ peptide' or ⁇ peptide' refer to a human amyloidogenic peptide that derives from APP by proteolytic cleavage.
- Various pathogenic forms of ⁇ peptides include ⁇ 1-42, ⁇ 1-40, ⁇ 5- 42, etc. (the numbers following ⁇ refer to the starting and ending positions in the amino acid sequence) .
- the amino acid sequence of the human ⁇ 1-42 peptide is the following:
- 'protein folding' is the physical process by which a polypeptide folds into its characteristic and functional three-dimensional structure from random coil. The correct three-dimensional structure is essential for biological activity. Failure to fold into native structure produces inactive proteins that are usually toxic. Several neurodegenerative diseases are believed to result from the accumulation of amyloid fibrils formed by misfolded proteins.
- 'intrinsically disordered proteins' are proteins which lack stable tertiary and/or secondary structure in solution yet fulfill key biological functions.
- a protein may undergo reversible structural changes in performing its biological function.
- the alternative structures of the same protein are referred to as different
- 'peptide' when used in reference to an agent that binds amyloid or amyloid-like deposits refers to a peptidic compound made up of 2, 3, 4, 5, 6, or more amino acid residues in length, and also includes amino acid residues with D or L stereochemistry.
- a peptide' as used in this context specifically excludes an antibody or an antigen-binding fragment (e.g. an Fab) of an antibody, and also an amyloidogenic sequence, such as ⁇ 1-40, which aggregates with other like molecules and forms a ⁇ -sheet structure.
- 'peptidomimetic' also referred to as 'peptide mimetic' , means any compound containing amino acid residues, whether D- or L-, whether natural or non-naturally occurring, and it can also comprise non-amino acid moieties.
- a 'peptidomimetic' is designed to mimic the biological action (s) of a natural mimicked peptide, including, for example, those designed to mimic the structure and/or binding activity (such as, for example, hydrogen bonds and hydrophobic packing interactions) of the peptides according to the methods disclosed herein.
- the term 'pentapeptide' refers to a compound of five amino acids, modified amino acids or amino acid substitutes.
- the compound apape (SEQ ID NO: 51) is a pentapeptide consisting of D-Ala, D-Pro, D-Ala, D-Pro and D- Ala-amide .
- the term 'resistant to. rotease digestion' or 'enzymatically resistant' entails that a given folded form of a polypeptide is cleaved at least 25% less than an alternatively folded form of that polypeptide when both forms are contacted with a similar amount of a given protease enzyme under the same conditions.
- a peptidomimetic is 'resistant to protease cleavage' if it is cleaved at least 10% less (and preferably 20, 30, 40, 50, 60, 70, 80, 90 or even 100% less) by a given amount of a given protease, relative to the cleavage of a corresponding peptide under like conditions.
- ⁇ reduce' or ⁇ inhibits' refers to at least a 10% decrease of the parameter being measured in the presence of an agent relative to the absence of that agent.
- 'reducing neurotoxicity' means inhibiting the toxic effect of a composition or environment against neural cells or tissue by at least 10% relative to cells or tissue not treated in a manner to reduce such toxic effect.
- 'neurotoxicity describes the ability of a substance, condition or state to impair, or even kill the functioning of a neural tissue or cell.
- 'binding' encompasses physical association of one molecule with another. Binding can be both covalent and non-covalent interatomic and intermolecular interaction, whether long lasting or transient. Examples include, without limitation, ionic bonds, hydrophobic interactions, hydrogen bonds, Van der Waals forces and dipole-dipole bonds.
- 'neuronal cell' refers to a cell of the central nervous system, including, but not limited to a neuron and a glia.
- 'screening test' encompasses tests conducted to determine if candidate inhibitory peptides are effective in disrupting ⁇ toxicity. Examples of such screening tests are described herein. However, a person of ordinary skill would recognize that other screening tests can be employed without departing from the spirit and scope of the invention.
- Example 1 Design of small peptides inhibiting amyloid toxicity
- Oligomerization and aggregation of some polypeptides and proteins appears to be a key factor in the neurodegeneration process in a group of diseases (e.g. AD) .
- the soluble forms of neurotoxic/synaptotoxic ⁇ -amyloid peptides ( ⁇ -1-42 oligomers and protofibrils) have no definite conformations, only some secondary structural elements (e.g. ⁇ -sheet parts) .
- the ⁇ - peptides belong to the family of intrinsically disordered proteins (IDP) . These proteins interact non-specifically with a big number of important cellular proteins causing neuronal dysfunction.
- IDP intrinsically disordered proteins
- novel neuroprotective compounds (see Table 2.) bind to the soluble, toxic ⁇ oligomers and protofibrils via a salt bridge and apolar interaction (s) .
- the novel class of compounds acts as ⁇ -amyloid structure modifying agents. These novel compounds convert the intrinsically disordered ⁇ - peptides to nontoxic conformation, and then initiate their aggregation to big, non-toxic ⁇ -aggregates . Simultaneously, the novel class of compounds stimulates the formation of dendrites and improves communication between the neurons, and thereby decreases the detrimental effect of ⁇ -peptides in the brain .
- the resin was resuspended in DCM, then the Boc-protecting group was removed with 50% TFA/DCM (5+25 min) .
- the peptide-resin was washed 3x with DCM then neutralized as detailed above and a new cycle was started.
- the peptide was cleaved from the resin with HF (cleavage cocktail: 10 mL HF, 0.8 mL dimethyl-sulfide and 0.2 mL anisole for 1 g of peptide-resin, 0 °C, 45 min) .
- the crude peptide was precipitated with diethyl-ether , dissolved in 50% ACN/water and lyophilized.
- PPPA-NH2 PAPA-NH2 , AC-EPAP-NH2, EPA-NH2, AC-EPA-NH2, EPP-NH2, DPA-NH2, DP-NH2, Succinyl-PA-NH2 , Succinyl-pa-NH2 and Glp-Asp- NH2 were synthesized with Fmoc-chemistry.
- the resin was resuspended in DMF, and the Fmoc group was removed as detailed above. Cycles were repeated until the required sequence was obtained.
- the peptide was cleaved from the resin using a mixture of TFA (95%) , water (2%) , triisopropyl-silane (1.5%) and dithiothreitol (1.5%). The cleavage was performed on 0 °C for 15 min, then at room temperature for 2 hours 45 min. The crude peptide was precipitated with diethyl-ether, dissolved in 50% ACN/water and lyophilized.
- Peptides were analyzed and purified using RP-HPLC. 0.1 % TFA in d.i. water and 80% ACN, 0.1% TFA in d.i. water was used as eluent A and eluent B, respectively. Analytical analysis was done on a Hewlett-Packard Agilent 1100 Series HPLC apparatus using a Luna C18 column (100 A, 5 ⁇ , 250x4, 60 mm, Phenomenex) , the flow rate was 1.2 mL/min and the gradient was as it is indicated in Table 2.
- Preparative chromatography was done on a Shimadzu HPLC apparatus equipped with a Luna C18 column (100 A, 10 m, 250x21.2 mm, Phenomenex) with a flow rate of 4 mL/min. The gradient was 0-30% eluent B in eluent A over 60 min.
- Mass spectrometry measurements were done on a FinniganMat TSQ 7000 mass spectrometer in ESI-MS mode.
- TEM Transmission electron microscopy
- Oligomeric and fibrillar structures of ⁇ 1-42 were prepared from iso- ⁇ 1-42 (75 ⁇ ) as published (Bozso et al. Peptides 31: 248-256, 2010).
- Ten ul droplets of ⁇ 1-42 solution (75 ⁇ ) with or without apape (SEQ ID NO: 51) (1:5 molar ratios) were placed on formvar-carbon coated 400 mesh copper grids (Electron Microscopy Sciences, Washington, PA, USA) and stained negatively with uranyl acetate.
- the aggregates were characterized by transmission electron microscopy with a Philips CM 10 transmission electron microscope (FEI Company, Hillsboro, Oregon, USA) operating at 100 kV. Images were taken by a Megaview II Soft Imaging System at magnifications of x
- Spectra of peptide solutions in the 200-250 nm wavelength region were recorded at 37 °C and 100 nm/s scan speed over a one week period at the following time points: 0 min, 10 min, 20 min, 30 min, 1 h, 3 h, 6 h, 24 h, 48 h, 72 h, 168 h. Spectra presented here are accumulations of 10 scans and the corresponding solvent spectra similarly recorded were subtracted.
- the fibril model is based on the NMR structure published by Liihrs et a. (PNAS 102/48: 17342-17347, 2005) and contains eight ⁇ 1-42 monomer units. The missing residues at the N-terminal part were completed assuming a ⁇ -structure. The accomplished structure was embedded into explicit water (TIP3P type) environment and 4 ns long molecular dynamics simulation was performed with the help of the AMBER8 program package (Case et al. AMBER 8, University of California, San Francisco, 2004) applying the FF03 forcefield with its own atomic charges.
- Replica-Exchange Molecular Dynamics (REMD) calculations with 24 trajectories were performed for each molecule between 280 - 430 K using explicit water (TIP3P) environment. 50 ns long simulations were accomplished in all cases by the GROMACS package (Hess et al. J. Chem. Theory Comput . 4: 435-447, 2008) applying the amber99sb forcefield (http://ambermd.org). Taking the trajectory at the lowest temperature, cluster analyses were performed at the 10 -50 ns interval by the ptraj program from the AmberTools package (http://ambermd.org).
- FIG. 2 It was observed that the apape peptide (SEQ ID NO: 51) (in 1:5 molar ratios) promoted the formation of the fibrillar aggregates, which formed already after 4 h of incubation, while the control sample contained only protofibrils and high-n oligomers. The presence of fibrillar aggregates could be observed in both samples after 24 h.
- SEQ ID NO: 51 acts as an aggregation promoter instead of an aggregation inhibitor of the beta amyloid.
- ECD spectra of the ⁇ 1-42 shows a strong minimum at 200 nm and another peak at 215 nm, indicative of a mixture of random and ⁇ -sheet structures even right after the dissolution of the peptide sample (Fig. 3A) .
- apape-NH2 displayed a random structure by itself and spectra recorded in later time points were not different from the one acquired immediately after dissolution of the sample (Fig. 3B) . This suggests that no major structural change of the pure peptide takes place during the one week period.
- Spectra recorded for the 1:5 molar ratio mixture of ⁇ 1-42 and apape-NH2 appears to be a simple combination of the spectra of the pure component peptides.
- the aggregation iso-amyloid ⁇ 1-42 in the presence of apape-NH2 appears to be less gradual as compared to the case of pure iso- amyloid ⁇ 1-42.
- a major structural change was observed after 6 hours. However, after the initial lagging period, structural transformation comes to completion similarly to that observed in the absence of apape-NH2.
- Difference spectra obtained by subtracting the corresponding pure apape-NH2 spectra from those of the ⁇ 1-42 and apape-NH2 mixture are markedly different from those recorded for pure ⁇ 1-42. The most conspicuous difference is the blueshift of the 215 minima, which indicates a small-scale structural change (Fig. 3C-D) .
- Such structural change may take place as a result of an intermolecular interaction between the two component peptides.
- the presence of apape-NH2 may slightly affect the aggregation kinetics of ⁇ 1- 42 as indicated by spectra of Fig. 3D. However, this difference in the aggregation behaviour is less apparent in the difference spectra shown on Figs. 3C and D.
- Example 2 In vitro studies of the neuroprotective effect of the peptides NaCl, KC1, CaC12, MgCl2, HEPES, NaHC03, D-Glucose, MIT and 96- well plates (Costar) were purchased from Sigma-Aldrich (Hungary) . The ExViS mini-chamber system was from our institute. The animal protocols applied in this study had been approved by the National Institute of Health and by the University of Szeged; permission number: 1-02442/001/2006.
- Brain slices (400 ⁇ thick) were prepared from the hippocampus with a Mcllwain tissue chopper at 4 °C in ice cold H-ACSF/1 solution followed by taking photos of them (for measuring slice area) .
- the Petri dish was stirred continuously at 370 rpm (modified BIOSAN TS-100 thermo shaker) .
- the Petri dish content (supernatant) was changed to the normal H- ACSF/1 solution (2 ml/Peri dish) .
- the slices were rapidly transferred into the ExViS mini-chamber (maximum 10 slice in 1 ml) for treating with ⁇ 1-42 (50 ⁇ stock solution into 950 ⁇ per chamber; 20 ⁇ ⁇ 1-42 in final concentration) .
- the peptidomimetics were used in 40 ⁇ and 100 ⁇ final concentration, alone or together with ⁇ 1-42 (mixed in DW before slice treatment) .
- 0.1 ml MTT stock solution 5 mg/ml H-ACSF/1
- H-ACSF/1 stock solution 5 mg/ml H-ACSF/1
- the optical density (OD) of the dissolved formazane was measured at 550 and 620 nm.
- the following formula: (OD550 - OD620)/area of slice (mm2) 100% in control ( ⁇ 1-42 untreated slices) was used for data synchronization.
- Table 3 summarizes the results of the MTT-assay of several novel peptides in two concentrations. It can be seen that among the peptides studied pape-NH2 has the least protective effect against and all the other peptides studied almost completely eliminated the toxic effect of ⁇ . On the basis of these results, we have selected apape (SEQ ID NO: 51) as the leading compound for further biological experiments.
- the synthesized ⁇ 1-42 was dissolved in 1,1,1,3,3,3- hexafluoro-2-propanol (HFIP) and incubated overnight at ambient temperature. After removal of the HFIP in vacuo, the peptide was dissolved in d.i. water and incubated at 37 °C for 3 days. Fibrils were collected by centrifugation at 10 000 x g for 15 min and the pellet was washed with d.i. water and lyophilized. Prior to use, the peptide was freshly dissolved in pH 6.4 saline to a final concentration of 5x10-5 M, gently sonicated for 15 min in order to facilitate the homogenization of the sample, and used in the biological experiments.
- HFIP 1,1,1,3,3,3- hexafluoro-2-propanol
- Extracellular recordings and microiontophoresis Extracellular single-unit recordings were performed in the rat hippocampus (Wistar male 250 to 330 g) after chloral hydrate anesthesia (intraperitonial, i.p. 0.4 g/kg initial dose, supplementary doses as required) .
- the animals were handled and surgery performed in accordance with the European Communities Council Directives (86/609/ECC) and the Hungarian Act for the Protection of Animals in Research (XXVIII. tv. Section 32). Ethical approvement number was 1-74-13/2010. All efforts were made to minimize pain and reduce the number of animals used.
- the head of each animal was mounted in a stereotaxic frame, the skull was opened above the hippocampus (a-p:-3.8 mm from bregma; lat: ⁇ 2 mm from the midline on either side), and the dura mater was carefully removed. Following a 1 hour recovery period, single-unit activity of the CAl hippocampal neurons was recorded extracellularly between depths of 2 and 3 mm by means of a low-impedance ( ⁇ 1 ⁇ ) 7 ⁇ carbon fiber-containing multibarrel microelectrode ( ation Scientific, Minneapolis, N, USA) , and drugs were delivered from the surrounding capillary barrels. Action potentials were amplified by an ExAmp-20KB extracellular amplifier (Kation Scientific) and monitored with an oscilloscope.
- the filter bandpass frequencies were 300 to 8000 Hz.
- a window discriminator (WD-2, Dagan Corporation, MN, USA) was used for spike discrimination.
- the amplified signals were sampled and digitalized at 50 kHz.
- the number of action potentials per second was counted by the computer and peristimulus time histograms were calculated and displayed in line.
- Iontophoretic drug delivery and experimental data collection were governed by a PCI-1200 multifunction instrument control and data acquisition board (National Instruments, Austin, TX, USA) placed in a computer programmed in LabVIEW 6, and by iontophoretic pumps (Minion-16 and BAB-350, Kation Scientific) .
- a multibarrel electrode affixed to the recording electrode was used for iontophoretic ejection of the following drugs: (a) 100 mM NMDANa (Sigma-Aldrich, Budapest, Hungary) in 100 mM NaCl (pH 8.0); (b) 5 ⁇ 10-5 M ⁇ 1-42 and (c) 2.5 ⁇ 10-4 M peptides dissolved in saline (pH 6.4); (d) a mixture containing ⁇ 1-42 (5 ⁇ 10-5 M) and the peptides to be studied (2.5 x 10-4 M) stored for 1 h, and (e) to mark the position of the electrode, 4% Pontamine Sky Blue (BDH Chemicals, Poole, England) in 100 mM sodium acetate.
- drugs (a) 100 mM NMDANa (Sigma-Aldrich, Budapest, Hungary) in 100 mM NaCl (pH 8.0); (b) 5 ⁇ 10-5 M ⁇ 1-42 and (c) 2.5 ⁇ 10-4 M
- the ⁇ 1-42 was ultrasonicated for 15 min prior to use. Neurons were excited by repetitive iontophoresis of NMDA at 1 min intervals for 5 s by applying negative iontophoretic currents ranging from 5 to 100 nA and the ejection current was selected so that the maximum firing rate fell between 30 and 80 spikes/s. Retaining current of the opposite direction in the range 2-21 nA was used. The peristimulus time histograms of the neurons were recorded. After establishment of a stable control, the peptides to be tested were co-iontophorized for 3 min at +100 nA, followed by ⁇ 1-42 for 1 min at -0.5 ⁇ .
- Extracellular single-unit recordings were obtained from 72 CA1 neurons from a total of 32 anesthetized rats. Pentapeptides were administered i.p. (0.5 mg/100 g) , and peristimulus histograms were then taken. The data from all 40-min intervals were pooled and means ⁇ SEM of percentage values were calculated.
- the pre- ⁇ 1-42 control firing rate was set between ⁇ 30-80 spike/sec. In that way, the rate of amyloid induced excitation was not dependent of the initial firing rate.
- the pre- ⁇ 1-42 firing values were considered as 100% at each recording, and the maximum post ⁇ 1-42 firing rates in % value were used for statistical evaluations.
- the maze consisted of a circular pool (diameter: 130 cm, height: 60 cm). The pool was filled to a depth of 40 cm with water (23 ⁇ 1 °C) containing milk. The pool was divided into four virtual quadrants. A circular glassy platform (diameter: 10 cm) was placed in the middle of one of the four quadrants of the pool. The location of the platform was the same during five days. The platform was submerged 1.5 cm below the water surface, so that it was invisible at water level. There was a black curtain around the pool. We placed different geometric shapes in all four directions on the curtain. The tank was placed in a dimly lit, soundproof test room.
- the experiment lasted for five days.
- the mice swam every day two times (two trials) and were placed into the water facing the wall of the pool. The time interval between each trial sessions was 30 seconds.
- the animals had 90 seconds to find the platform, and 15 seconds to stay on it. Those animals, which did not find the platform were gently guided and placed on it until 15 seconds. The animal was taken to its home cage and was allowed to dry up after the end of the two trials.
- the animals were anaesthetized with 5 % chloral hydrate (400 mg/bwkg) and perfused transcardially with physiological saline followed by 4% paraformaldehyde in phosphate buffer (0.2 M, pH 7.4).
- the brains were carefully removed from the skull, postfixed for 1 day in 4% paraformaldehyde, and then left for 2 days in phosphate-buffered saline containing 30% sucrose and 0.01% sodium azide at 4°C.
- Fifty i thick cross sections were cut and mounted onto gelatine-coated microscopy slides for Nissl staining. The slides were rinsed in 0.2 M PBS, and stained in 0.5% cresyl violet acetate for 1.5-2 minutes.
- the slides were rinsed again in PBS for 20-30 seconds.
- the slides were immersed consecutively in 70%, 80% and 95% ethanol followed by absolute alcohol and 99% butanol for 20-30 seconds.
- slides were placed in Hellendal staining jars containing xylene and mounted with DPX.
- the slides were scanned in a Zeiss MIRAX MIDI Slide Scanner (Carl Zeiss Inc., Germany). The left and right side of the hippocampus were annotated and the HistoQuant software (3D Histech Kft . , Budapest, Hungary) was used to calculate the density of cells.
- the animals were anaesthetized and perfused as above. Their brains were dissected and hippocampus isolated. Fifty ⁇ thick cross sections were cut in a cryostat. The sections were collected into wells containing PBS and processed for immunohistochemistry. Monoclonal mouse anti-human PHF-tau (paired helical filament tau), clone AT100 antibody (1:800 diluted) was used as the primer antibody (Thermo Scientific, Rockford, IL, U.S. A). Biotinylated anti mouse IgG (1:400 diluted) (Vector Laboratories, Inc. Burlingame) was used as a secondary antibody. Vectastain ABC kit (Vector Laboratories Inc.) was used to visualize the secondary antibody.
- Monoclonal mouse anti-human PHF-tau (paired helical filament tau), clone AT100 antibody (1:800 diluted) was used as the primer antibody (Thermo Scientific, Rockford, IL, U.S. A).
- the peroxidase reaction was developed with 3, 3 ' -diaminobenzidine tetrahydrochloride (DAB Sigma Aldrich Co. Ltd.) enhanced with 1% nickel-ammonium-sulphate.
- DAB Sigma Aldrich Co. Ltd. 3, 3 ' -diaminobenzidine tetrahydrochloride
- nickel-ammonium-sulphate 1% nickel-ammonium-sulphate.
- the f ee-floating slices were mounted on slides and digitally scanned in a Zeiss MIRAX MIDI Slide Scanner (Carl Zeiss Inc., Germany).
- the left and right side of the hippocampus were annotated and the HistoQuant software (3D Histech Kft., Budapest, Hungary) was used to calculate the number of tau immunopositive cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to peptides and peptidomimetics useful for reducing the neurotoxicity of amyloid peptide aggregates or prion-like (prionoid) protein aggregates, the invention further relates to pharmaceutical compositions containing said peptides and/or peptidomimetics, to the use of said peptides and/or peptidomimetics in the manufacture of medicines useful for the prophylaxis or treatment of diseases that can be cured by protection against the detrimental effect of Αβ-peptides /abnormal Αβ aggregation leading to amyloid plaque formation, and it relates to the use of said peptides and/or peptidomimetics in the prophylaxis or treatment of the above mentioned diseases. The invention aimed at developing treatments of neurodegenerative diseases, particularly Alzheimer's disease (AD), during which accumulation of misfolded and/or aggregated proteins occurs.
Description
Small Peptide inhibitors of β-amyloid toxicity
Field of the invention
The invention relates to peptides and peptidomimetics useful for reducing the neurotoxicity of amyloid peptide aggregates or prion-like (prionoid) protein aggregates, the invention further relates to pharmaceutical compositions containing said peptides and/or peptidomimetics, to the use of said peptides and/or peptidomimetics in the manufacture of medicines useful for the prophylaxis or treatment of diseases that can be cured by protection against the detrimental effect of Αβ-peptides /abnormal Αβ aggregation leading to amyloid plaque formation, and it relates to the use of said peptides and/or peptidomimetics in the prophylaxis or treatment of the above mentioned diseases. The invention aimed at developing treatments of neurodegenerative diseases, particularly Alzheimer' s disease (AD) , during which accumulation of misfolded and/or aggregated proteins occurs.
The following abbreviations are used throughout the present description :
Αβ, β-amyloid peptide; AD, Alzheimer's disease; PD, Parkinson's, Disease; Ac, acetyl; ACN, acetonitrile; APP, amyloid precursor protein; APP x PS1, APP/ presenilin 1 (PS1) mouse model of AD; apape, pentapeptide of SEQ ID NO: 51; Boc, terc-butyloxycarbonyl; BSB, β-sheet breaker; DCC, N,N- dicyclohexylcarbodiimide; DCM, dichloromethane; DIPEA, diisopropylethylamine; DMF, N, N-dimethylformamide; Fmoc, flourenylmethoxycarbonyl; GPCR, G protein coupled receptor; HFIP, 1, 1, 1, 3, 3, 3-hexafluoro-2-propanol; HOBt, 1-
hydroxybenzotriazole; IDP, intrinsically disordered protein; i.p., intraperitoneal; LTP, long-term potentiation; NT, neurofibrillary tangles; MBHA, 4-methylbenzhydrylamine ; MWM, Morris water maze; NMDA, N-methyl-D-aspartic acid; PAM, 4- hydroxymethylphenylacetamide; PBS, phosphate buffered saline; TFA, triflouroacetic acid; Thioflavin-T (ThT) ; ACN, acetonitrile; Boc, tert-butyloxycarbonyl ; DCC, N, N- dicyclohexylcarbodiimide; DCM, dichloromethane ; DIPEA, diisopropylethylamine; DMF, N, N-dimethylformamide; EDCxHCL 1- Ethyl-3- [3-dimethylaminopropyl] carbodiimide hydrochloride;
NH2, C-terminal amide group; MBHA 4-methylbenzhydrylamine; PAM, 4-hydroxymethylphenylacetamide; TFA, triflouroacetic acid.
Abbreviations of non-standard amino acids and similar moieties (abbreviations of standard amino acids are known by the person skilled in the art) :
Aib, 2-aminoisobutyric acid; ala, D-alanine; pro, D-proline; glu, D-glutamic acid; asp, D-aspartic acid; Glp, L- pyroglutamic acid; Sar, sarcosin; Pip, L-pipecolic acid; sue, succinyl; GABA, gamma-aminobutyric acid; Abu, 2-aminobutyric acid; Tic, Tetrahydro-isoquinoline-3-carboxylic acid.
As obvious for a person skilled in the art chiral amino acids can have either L- or D-configuration . If an amino acid is mentioned in the present description both L- or D- configuration has to be understood, unless the configuration is specified.
Background of the invention According to the 2010 World Alzheimer Report, the number of people with Alzheimer's or other dementia was about 35.6
million, which number is expected to nearly double in every 20 years. Worldwide, the economic cost of dementia has been estimated as USD 315 billion annually. AD, the most common of senile dementias, is a global health crisis with devastating effects on individuals, families and societies. There is an urgent need to develop efficient and relatively cheap treatments for the early stage of the disease and/or prevention strategies to replace currently available medications which only reduce the symptoms and the progression of the disease but does not solve the underlying problem.
Several diseases, including for example AD, Parkinson's disease, type II diabetes, and amyloidosis are associated with the transformation of normally soluble proteins into amyloid fibrils (Dobson, Trends Biochem Sci. 24 ( 9) : 329-32, 1999; Sipe and Cohen, J Struct Biol 130 (2-3 ): 88-98 , 2000). Two distinct types of fibrillar aggregates were found in AD brain samples: amyloid plaques comprising deposits of Αβ and neurofibrillary tangles consisting of tau, a microtubule-associated protein (Selkoe, J Alzheimers Dis 3(l):75-80, 2001). Αβ aggregates are mainly β-sheets with all the hallmark characteristics of amyloid fibrils, including a cross-beta diffraction pattern and characteristic staining by the dyes Congo Red and thioflavin T (Eanes and Glenner, J Histochem Cytochem 16 (11) : 673-7, 1968; LeVine, Protein Sci 2(3):404-10, 1993; Sipe and Cohen, J Struct Biol 130 (2-3) : 88-98, 2000) . Tau filaments adopt various morphologies, including paired helical filaments, which are β- sheet rich fibrils that appear as twisted structures under electron microscopy, and straight filaments, which lack the twisted morphology (Goedert et al., Curr Opin Neurobiol 8(5): 619-32, Review, 1998). Tau filaments bind the dye thioflavine S (ThS) and yield fluorescent signal and have a cross-beta diffraction pattern (Berriman et al., Proc Natl Acad
Sci U.S.A. 100 (15) :9034-8, 2003; Friedhoff et al., Biochemistry 37 (28) :10223-30, 1998) .
AD is characterized by the formation of extracellular amyloid plaques, cerebrovascular amyloid deposits, intracellular neurofibrillary tangles (NT) and neuronal loss in the brain. While NTs mainly consist of the microtubule-associated protein tau (Selkoe, Physiol Rev 81: 741-766, 2001), the amyloid plaques contain large amounts of amyloid beta (Αβ) peptides (a length of 39-43 amino acids) , which are produced by the proteolytic cleavage of a much longer amyloid precursor protein (APP) in neurons and other cells throughout life (Haass et al. Nature 359: 322-325, 1992). According to the amyloid hypothesis it was suggested that dysregulation of APP processing is the key initiating event in AD pathogenesis, subsequently leading to increased levels and aggregation of extracellular Αβ (εΑβ) , specifically θΑβ 1-42 (that is, the 42 amino acid length version of Αβ) . Αβ oligomerization and/or fibrillogenesis trigger a cascade of cellular and molecular events, including disturbed axonal transport, development of synaptic failure, neuronal loss, reduction in neurotransmitter levels, all of which result in defects in cognition, synaptic plasticity and in development of tau pathology (Hardy and Higgins, Science 256: 184-185, 1992) . Some G protein coupled receptors (GPCRs) directly influence the amyloid cascade through modulation of a- , β- and γ-secretases that participate in the proteolysis of APP, and regulation of Αβ degradation. Additionally, Αβ has been shown to disturb the functioning of several GPCRs (Verdier and Penke, Curr Prot &. Peptide Science: 19-31, 2004; Verdier et al. J Neurochem 94: 617-628 2005). Extracellular Αβ triggers aberrant signaling and therefore may cause cognitive dysfunction and consequently neurodegeneration in the brain (Patel and Jhamandas Expert Rev Mol Med 14: e2 201; Xu et al. Prog Neurobiol 97: 1-13, 2012). Emerging insights into the link
between GPCRs and AD highlight the potential of this class of receptors as a therapeutic target for AD (for a review, see Thathiah and De Strooper, Nat Rev Neurosci 12(2): 73-87, 2011; United States Patent Application 0100137207, 2010) .
The original ^amyloid cascade' hypothesis has been radically changed several times during the last decade. Recently, the interest of AD researchers has turned to the intracellular Αβ peptides (ίΑβ) . It is now well accepted that two pools of Αβ exist in the brain: extra- and intracellular, and a dynamic relationship exists between them. More and more evidences suggest that θΑβ may have reduced impact on AD pathology and εΑβ depositions/plaques alone cannot be responsible for all kinds of AD pathology, e.g. like apoptotic cell death. Hartmann published already in 1999 the formation of ίΑβ (and specially its highly toxic ίΑβ 1-42 species) in different subcellular organelles (Hartmann Eur Arch Psychiatry Clin Neurosxci 249: 291-298, 1999) . The λ intracellular Αβ hypothesis' (LaFerla et al. Nat Rev Neurosci 8: 499-509, 2007) assumes that ϊΑβ accumulation is the early, causative event in AD development. ίΑβ is the cytotoxic substance and eAp deposition (in the later stage of AD) is rather the result of cell death and destruction. Mechanism of amyloid plaque formation also suggests an intracellular basis of Αβ pathogenecity (Friedrich et al. Proc Natl Acad Sci USA 107: 1942-1947, 2010). A series of review articles have summarized the mechanism of ίΑβ accumulation and the results of ίΑβ studies performed during the last ten years (LaFerla et al. Nat Rev Neurosci 8: 499-509, 2007; Gimenez-Llort et al. Neurosci Biobehav Rev 31: 125-147, 2007; Li et al. Prog Neurobiol 83: 131-139, 2007; Gouras et al Acta Neuropathol 119: 523-541, 2010; Bayer and irths Nervenartz 79Supp3: 117, 2010; book chapter review on the role of ίΑβ (Zhang in: Jelinek, R. (Ed.), Lipids and cellular membranes in amyloid diseases, Wiley 2011, pp. 143-159) . ίΑβ
has been widely detected in neuronal cells and primary human neurons, and shown to have a broad range of interaction with proteins and subcellular organelles. Studies in several mouse models of AD with intraneuronal Αβ-expression and accumulation (Casas et al Am J Pathol 165: 1289-1300, 2004; Billings Neuron 45: 675-688, 2005; Tomiyama J Neurosci 30: 4845-4856, 2010; Abramowski et al. J Neurosci 32: 1273-1283, 2011) have proven that ϊΑβ causes the onset of early AD cognitive deficits in transgenic mice.
Another hypothesis for understanding AD focuses on the microtubular protein tau (Iqbal et al. Acta Neuropathol 109 (1) :25-312, 2009). Tau is an important protein in AD pathology: the Braak staging of the disease (Braak and Braak Neurobiol Aging 16(3):271-8, 1995) is based on the localization of tau deposits in brain structures. Similarly to Αβ, hyperphosphorylated tau can also form toxic intracellular aggregates. As a consequence of formation of tau deposits, the microtubular system collapse and the axonal transport fails (Iqbal et al. Acta Neuropathol 109 (1) : 25-312, 2009; Takashima Curr Alzheimer Res 5(6): 591-8, 2008), which results in neuronal dysfunction and cell death.
Recently, the two hypotheses for AD etiopathology were combined (Small and Duff Neuron 60: 534-542, 2008). AD is regarded as a special form of tauopathies with primacy of Αβ, that is accumulation of εΑβ, and ίΑβ starts the pathological processes of AD. Both species of Αβ trigger tau-hyperphosphorylation, however, tau protein is also required for Αβ-induced neuronal dysfunction (Shipton et al. J Neurosci 31: 1688-1692, 2011).
The newest theory of Ittner and Gotz (Nature Rev Neuroscience 12, 67-72, 2011), the 'tau axis' hypothesis allows the primacy of Αβ, however, it puts tau and its effects in the dendritic
compartment of neurons in the center stating that Αβ-toxicity is tau dependent. Αβ causes tau hyperphosphorylation and detaching from microtubules. Simultaneously, the progressively increasing level of dendritic tau makes neurons vulnerable to Αβ and it is linked to increased tau hyperphosphorylation, thereby establishing a vicious circle. As Αβ is the inducer of pathological processes its effects should be neutralized.
For two decades AD drug research has used the amyloid cascade hypothesis. Putative neuroprotective agents were tried in the pipeline that selectively block Αβ aggregation and/or enhance clearance of Αβ peptides. Beside the traditional organic compounds, which were reported to reduce or inhibit the aggregation and toxicity of Αβ (Kisilevsky et al. Nat Med 1(2): 143-148, 1995; Wood et al. J Biol Chem 271(8): 4086-4092, 1996) , several other approaches have been developed to reduce neuronal loss (neuroprotection) caused by Αβ. One of them is targeting the risk factors in an attempt to neutralize or inhibit their action. In the presence of β- and γ-secretase inhibitors, Αβ 1-42 is not formed. However, these enzyme inhibitors show poor specificity combined with undesirable side effects. Other inhibitors block the interaction between Αβ 1-42 and membranes, e.g. amyloid surface binding molecules, competitive inhibitors (RGD - peptides) and Memantine® /NMDA. Αβ immunization was also considered as another promising approach for AD therapy. However, clinical studies revealed a strong brain inflammatory response in immunized patients (Munch and Robinson, J Neural Transm 109(708): 1081-1087, 2002). Dramatic advances in understanding the neurobiology of AD have revealed a new direction for drug development, e.g. the identification of specific aggregation states of Αβ (for a review, see Broersen et al., Alz. Res Ther 2/12: 1-14, 2010). Recently, a self propagating special conformation that could
transmit AD from neuron to neuron was identified (Aguzzi and Falig, Nature Neurosci. 15(7) 936-939, 2012). Recent studies have shown that AD severity correlates more closely with soluble oligomeric than the fibrillar forms of Αβ (McLean et al. Ann Neurol 46: 860-866, 1999; Lue et al . Am J Pathol 155: 853-862, 1999) . Αβ monomer is non-toxic and unstructured in solution, but acquires a β-sheet structure on aggregation and amyloid formation. It has been suggested that amyloid formation is a nucleation-polymerization reaction, that is characterized by an initial lag phase dominated by monomeric (M) species, followed by the formation of low-molecular weight (LMW) soluble oligomers (dimer, trimer and < 8-mers) . The β-sheet rich oligomeric intermediates are referred to as prefibrillar aggregates, which disappear upon fibril formation. Some of the key features of protofibrils are: (i) they contain a mixture of different secondary structural elements with a predominance of β-sheets; (ii) bind amyloid-specific dyes, e.g. Congo red and Thioflavin-T (ThT) ; and (iii) are less stable than mature fibrils. Amyloid fibrils are insoluble, β-sheet rich structures that contain 2-6 protofilament subunits. Thus, the key pathogenic event in the onset of AD is believed to be the formation of soluble forms of neurotoxic/synaptotoxic β-amyloid peptides (A β 42 oligomers and protofibrils), which are intrinsically disordered proteins that possess many metastabil conformational states, thereby able to interact with several proteins of the neural cells (Tompa FEBS J 276 (19) : 5406-15, 2009; Broersen et al. Alzheimer's Res & Therapy 2(4): 12-14, 2010) . Understanding the precise chemical nature of the toxic Αβ oligomeric species is an important goal that may ultimately help the design of specific molecules, which will be able to correct a particular cellular dysfunction by restoring normal signal transduction and the ability of nerve cells to communicate .
W
9
Based on the findings in the field, a strategy was to design inhibitory peptides of various types and conformations, which were directed to block Αβ aggregation or to dissolve amyloid fibrils (for a review, see Fiilop et al. Research Signpost 37/661 82, 161-188, 2009) . However, the results have not confirmed the nature and conformation of the Αβ species that are responsible for transmission of the disease from cell to cell, thus the design of the first series of inhibitory peptides was unsuccessful.
In the past five years strong experimental evidences from AD and PD model systems demonstrated that infectious substance can be generated in vitro using different proteins. This breakthrough has proven that a misfolded protein is the active component of the infectious agent. This finding binds AD to prion diseases. According to the protein only' hypothesis, infectious prions are composed predominantly, if not entirely, of aggregates of misfolded, host-encoded, cellular prion protein (PrPSC) (Griffith Nature 215:1043-44, 1967). PrPSC arises from normal PrPC through conformational conversion and then PrPSC accumulates predominantly in the extracellular space .
Thus Αβ may be directly toxic to neuronal cells and synapses. The intrinsically disordered (ID) structures of Αβ represent transient intermediates in the aggregation cascade in patient brains. The pathology of AD, the Braak stages (Braak H. and Braak E. Neurobiol. Aging 16:271-278, 1995) also support the idea that AD spreads from neuron to neuron. It is almost forgotten that at the beginning of eighties-nineties and AD- research, the disease was suspected of being a prion disease (Prusiner Biochemistry 23(25): 5898-906, 1984; Gajdusek Mol Neurobiol 8(1): 1-13.1994). Recently, it was demonstrated, that extracts containing soluble Αβ aggregates induce amyloidosis in mice that otherwise never develop amyloid plaques (Morales et
al. Mol Psychiatry 17, 1347-1353, 2012). Pyroglutamylated Αβ 3- 42 shows prion-like behavior in mice (Nussbaum et al Nature 485: 651-655, 2012). Pathological similarities between AD and prion diseases suggest that the formation and spread of the proteinaceous lesions might involve a common molecular mechanism - corruptive protein templating (Eisele et al. Science 330: 980-982, 2010, Jucker and Walker, Ann Neurol 70: 532-540, 2011) . Experimentally, cerebral β-amyloidosis can be exogenously induced by exposure to dilute brain extracts containing aggregated Αβ seeds (seeding-nucleation model) . It has been shown recently that pure Αβ injections into the brain may induce plaques throughout the whole brain within 5 to 6 months (Stohr et al. Proc Natl Acad Sci U S A. 27, 11025-30, 2012) . If the peptides were injected to one hemisphere, plaque formation started in both halves of the brain. The amyloid- inducing agent probably is Αβ itself (Auer et al. Physa Rev Lett 101: 258101, 2008), in a special toxic conformation (synonyms :' hypertoxic Αβ' , ^primordial cytotoxic Αβ' , ^prionoid Αβ') generated most effectively in the living brain (Polymenidou and Cleveland, J Exp Med 209: 889-893, 2012). The term ^rionoid' was introduced by Aguzzi for self-propagating, transmissible protein aggregates (Aguzzi and Rajendran Neuron 64: 783:790, 2009). Infectious prions and prionoids can be prepared by protein misfolding cyclic amplification (PMCA) (Soto et al, TINS 25: 390394, 2002, Saa et al. J Biol Chem 281:' 35245-35252, 2006; Murayama et al. Neurosci Lett 413: 270-273, 2007; Soto and Satani Trend Mol Med 17: 14-24, 2011; Gonzalez- Montalban et al. PLoS Pathog 7:el001277, 2011; Moreno-Gonzalez and Soto Semin Cell Dev Biol 22: 482-487, 2011). The precise molecular mechanism of conversion of a non-transmissible protein molecule to the pathogenic form (e.g. PrPc→PrPSc) is not completely understood, but available data support the seeding-nucleation model in which the infectious conformer (e.g. PrPSc) is an oligomer that acts as a seed to bind native
protein (PrPc) and catalyze its conversion into the misfolded form by incorporation into the growing polymer (Soto et al. TINS 25: 390-394. 2002; Soto et al. TIBS 31: 150-155, 2006). It has remained unclear whether other compounds, besides the misfolded prion/prionoid protein, for example a co-factor, might be an essential element of the infectious agent. Such a co-factor might act as an essential catalyst for prion/prionoid conversion, help to stabilize the hypertoxic conformation and might increase the biological stability of prions/prionoids (Soto TIBS 36(3):151-8, 2010).
Summary of the invention As outlined above, there were several attempts to inhibit Αβ aggregation by small molecules (i.e. conventional organic compounds) , some of them are undergoing clinical trials (for a review, see Amijee and Scopes, J Alz Dis 17: 33-47, 2009). Taking in account the most recent results of AD research the amyloid peptide is the target of most AD-modifying therapies. A novel compound for the prophylaxis and treatment of AD should prevent the formation of toxic Αβ oligomers and the conformational change into infectious prionoid species. Such compound preferably also prevents any interaction between toxic extra- or intracellular Αβ and neuronal cell membranes, membrane proteins and intraneuronal as well as molecular organelles. If these interactions are hindered, Αβ cannot initiate tau-pathology, the release of lysosomal enzymes and apoptotic cell death.
Thus, the problem according the present invention is that an effective means is missing to inhibit Αβ aggregation to toxic oligomers in order to prevent or treat diseases that are the
consequence of Αβ aggregation, that is that can be cured by protection against the detrimental effect of Αβ-peptides.
Therefore the object of the present invention is to provide compounds that can effectively inhibit Αβ aggregation to toxic oligomers and inititate aggregation to big, non-toxic assemblies. These compounds will be useful in the prophylaxis and treatment of diseases associated with Αβ aggregation, wherein such diseases include, without limitation, neurodegenerative diseases, like AD and Parkinson's disease, Down syndrome, type II diabetes, amyloidosis etc.
Surprisingly, we found that members of the novel class of compounds according to the present invention act as β-amyloid structure modifying agents. Therefore, to solve the above outlined problem, the present invention provides a novel group of short peptides and peptidomimetics. These peptides - among other useful effects - inhibit Αβ aggregation. Briefly, the present invention relates to the following
peptides and peptidomimetics of the general formula (I) :
X-A1-A2-A3-A4-A5-Y (I) wherein
X is absent or represents: acetyl, propionyl, succinyl group Al is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, oi-methyl-Ala, Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, succinyl, Pro, acetyl, 2-amino-adipoic acid, propionyl group;
A2 is absent or represents: Pro, Tic, thiaproline, a-methyl-
Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid,
Glu, Asp, 2-carboxy-piperazine, succinyl, Glp, acetyl,
GABA, propionyl group;
A3 is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, α-methyl-Ala, Abu, norvaline, Asp, Glu, Glp, acetyl, succinyl, GABA, propionyl group;
A4 is absent or represents: Pro, Tic, thiaproline, a-methyl-
Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid,
Glu, Asp, 2-carboxy-piperazine, succinyl, Glp group;
A5 represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala,
Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, 2- amino-adipoic acid, Pro;
Y is absent or represents: amide, N-methylamide, or N, N- dimethyl-amide;
provided that if A2 is absent than Al is also absent and if A3 is absent than Al and A2 are also absent, and if A4 is absent than Al, A2 and A3 are also absent;
and to their pharmaceutically acceptable salts and esters.
As can be seen in the above general formula (I), the present invention relates to peptides containing from 1 to 5 amino acid moieties, where - apart from the naturally occuring amino acids - also some artificial amino acids and peptide chain ends are also present.
Al, A2, A3, A4 and A5 are selected in such a way that the resulting peptide or peptidomimetic bind to the natural Αβ, thereby modulating its aggregation properties and inhibits its neurotoxicity via a conformational change.
The present invention relates preferably to peptides and peptidomimetics listed in Table 2. (see below)
The present invention relates more preferably to peptides and peptidomimetics of the following formulas:
EPP-amide (SEQ ID NO 13),
ape-amide (SEQ ID NO 14),
GABA-pe-amide (SEQ ID NO 16),
DPA-amide (SEQ ID NO 17),
pppe-amide (SEQ ID NO 21),
EPAPA (SEQ ID NO 28) ,
EPPPA(SEQ ID NO 29) ,
epppa-amide (SEQ ID NO 32),
apapq (SEQ ID NO 46) ,
apapn (SEQ ID NO 48) ,
apape (SEQ ID NO 51)
and pharmaceutically acceptable salts and esters thereof.
Furthermore, the invention relates to pharmaceutical
preparations, which contain at least one peptide or
peptidomimetic of the general formula (I) , its salt and ester and at least one pharmaceutically acceptable additive.
Preferably this additive is a matrix ensuring controlled release .
The invention relates preferably to pharmaceutical
preparations, which contain at least one of the peptides or peptidomimetics of the following formulas: EPP-amide (SEQ ID NO 13),
ape-amide (SEQ ID NO 14),
GABA-pe-amide (SEQ ID NO 16),
DPA-amide (SEQ ID NO 17),
pppe-amide (SEQ ID NO 21) ,
EPAPA (SEQ ID NO 28),
EPPPA (SEQ ID NO 29) ,
epppa-amide (SEQ ID NO 32),
apapq (SEQ ID NO 46) ,
apapn (SEQ ID NO 48) ,
apape (SEQ ID NO 51)
and pharmaceutically acceptable salts and esters thereof. The invention also relates to the use of peptides and/or peptidomimetics according to general formula (I) and their pharmaceutically acceptable salt and ester in the manufacture of a pharmaceutical preparation suitable for the prophylaxis and/or treatment of diseases selected from the group of neurodegenerative diseases associated with Αβ aggregation, Down syndrome, type II diabetes, and amyloidosis.
Brief description of the drawings
Fig. 1 shows the TEM images of oligomeric and fibrillar structures of Αβ 1-42 prepared from iso-Αβ 1-42 (75 μΜ) at 0 min A) , 4 h B) , and 24 h C) in the absence and presence
of apape (SEQ ID NO: 51) (1:5 molar ratio).
Fig. 2 shows the effect of the apape pentapeptide on the size distribution of the amyloid aggregates (50 μΜ) . dH: hydrodynamical diameter, CG7: control peptide Cys-(Gly)7. The apape pentapeptide (1:5 molar ratios) facilitated the formation of large agregates of beta amyloid, which formed already after 4 h of incubation, whereas the control peptide did not show a similar effect. After 24 h the presence of fibrillar aggregates could be observed in both samples. Fig. 3 displays the ECD spectra recorded over a 168 h period for Αβ 1-42, apape-NH2 and a 1:5 molar ratio mixture of Αβ 1-42 and apape-NH2. Difference spectra were obtained by subtracting the corresponding pure apape-NH2 spectra from those of the Αβ 1-42 and apape-NH2 mixture.
Fig. 4 shows the backbone-fitted representatives of the indicated peptides obtained by cluster analysis. The ribbon is always fitted to the representative of the largest cluster.
Fig. 5 indicates the time-dependence of the signal intensity of apape in the presence of Αβ 1-42 in 1H NMR spectra (a). Concentrations were 250 μΜ for iso Αβ 1-42 and 1.9 mM for apape. After 24 hours, the bound fraction of apape was 3.5 % (diamond). In this case 66.5 μΜ apape bound to Αβ 1-42, which assumes 1:4 binding, respectively. The control signal intensity of apape without Αβ 1-42 was marked by square, (b) : After 1 week, the final value of the bound fraction of apape was 9 % (diamond). In this case, one apape can bind to one Αβ 1-42. The control signal intensity of apape without Αβ 1-42 was 100 ± 0.3 % during the examined period (square) . (c) : Scaled 1H NMR methyl signals of the free apape sample (dark grey) and apape + Αβ 1-42 after 24 hours incubation (light grey) . (d) : Signal assignment of apape; (e) : part of 1H NMR spectrum of apape. Shifting of the N-terminal Ala protons was observed upon addition of iso Αβ 1-42. Lower spectrum is the control apape spectrum and upper spectrum is after 24 hours addition of iso Αβ 1-42. Fig. 6 demonstrates that the peptide pape in vitro protects against the LTP impairment caused by Αβ 1-42 in mouse hippocampal slices. LTP was induced by theta burst stimulation (TBS) , and was followed for 75 min (A) . Panel B shows the mean for field excitatory postsynaptic potential (fEPSP) amplitudes 85-90 min after TBS. * p < 0.05 versus control; one-way ANOVA followed by Dunnett's test.
Fig. 7 shows the effect of intraperitonially administered apape and pentaglycine (GGGGG) on the NMDA response-enhancing effect
of Αβ 1-42 (the first grey bar) . The peptide apape had a protective effect between «50 and =250 min, and the control pentaglycine did not interfere with the Αβ 1-42-induced excitation. Mean of maximum NMDA-evoked responses, normalized by the control data (the total spike number during each excitation epoch before Αβ 1-42) ± SEM. Asterisks indicate significant differences, p < 0.05, n=4 for all data.
Fig. 8 depicts the neuroprotective effect of apape in the Morris water maze task in rats. Bar graphs show the mean ± SEM. Latencies to reach the platform in second on each of five days. Animals were divided into the following four groups: hydrogen carbonate buffer (HCBS) treated, physiological saline injected control (white); HCBS treated, apape (10 mg/bwkg, i.p.) injected (light grey) ; injected with oligomeric Αβ 1-42 (75 μΜ, aggregated for 136 h, i.e. v.) and apape (10.0 mg/bwkg, i.p.), (black) ; injected with oligomeric Αβ 1-42 (75 μΜ, aggregated for 136 h, i.c.v.j and physiological saline solution (i.p), (dark grey) . According to one-way ANOVA, the significant level between the groups on the third day F48.3=3.449, p=0.024. The asterisk denotes significant (p < 0.05) difference in the post hoc LSD test between the experimental groups on the third day.
Fig. 9 shows the neuroprotective effect of apape in the Morris water maze task in APP x PS1 mice. Bar graphs show the mean ± SEM. latencies to reach the platform in second on each of five days. Animals were divided into the following four groups: placebo injected, wild group (white) ; apape injected wild group (light grey); apape injected APPxPSl mice (black); placebo injected APPxPSl mice (dark grey) . According to the repeated measure of ANOVA we found significant differences between the groups (F30 4=10.480 p=0.0001), in post hoc LSD test the difference between the wild-placebo injected group, and the APPXPS1 placebo injected group on the fourth day p=0.001,
difference between the apape injected wild and APPXPSl group and the transgenic placebo injected group on the fourth day, p^0.0001. Fig. 10 shows the neuroprotective effect of apape during the first swimming in the Morris water maze task in APP x PS1 mice. Bar graphs show the mean ± SEM. latencies to reach the platform in second on each of five days. Animals were divided into the following four groups: placebo injected, wild group (white); apape injected wild group (light grey) ; apape injected APPxPSl mice (black) ; placebo injected APPxPSl mice (dark grey) . According to the repeated measure of ANOVA we found significant difference between the groups
p=0.002), in post hoc LSD test the difference between the wild-placebo injected group, and the APPXPSl placebo injected group on the fourth day p=0.002, difference between the apape injected wild and APPXPSl placebo injected group p<0.0001, furthermore difference between transgenic placebo injected mice and transgenic apape administered group p=0.037.
Fig. 11 displays tau histology in 50 micrometer thick hippocampal sections of female APPxPSl transgenic mouse strain. The vertical axis shows the mean of the number of tau immune positive cells in wild-placebo injected (white) ; APPxPSl transgenic-placebo administered (light grey) ; apape injected wild (black) ; and the apape injected transgenic (dark grey) animals. According to the one way ANOVA, the difference between the experimental groups was significant (F62, 3=15.642, p<0.0001) In the multiple comparisons post hoc LSD test we also found significant differences between the APPxPSl transgenic-placebo injected group and the other three experimental groups. Data are expressed as mean ± SEM.
Fig. 12 reports tau histology in 50 micrometer thick hippocampal sections of male APPxPSl transgenic mouse strain. Bar graphs show the mean of the number of tau immune positive cells ± SEM. For details, see Fig. 11. According to the one way ANOVA, the difference between the experimental groups was significant (Fie, 3=12.756, p<0.0001). The multiple comparisons post hoc LSD test shows significant difference between the transgenic-placebo injected and wild placebo injected, furthermore the wild-apape administered groups (p=0.001). Additionally, the number of tau positive cells was significantly higher in the APPxPSl transgenic-placebo injected group than in the APPxPSl-BFR-106 injected group.
Fig. 13 shows cresyl violet staining in 50 micrometer thick cross sections of hippocampus of female APPxPSl transgenic mouse strain. Bar graphs show the number of tau immune positive cells ± SEM. White: wild-placebo injected; light grey: APPxPSl transgenic-placebo administered group; black: wild-apape injected group; and dark grey: APPxPSl transgenic-apape injected animals. According to the one way ANOVA, the difference between the experimental groups was significant (F4i, 3=8.915) . In the multiple comparisons post hoc LSD test the wild-placebo injected group compared to the transgenic and wild-apape administered groups show significant difference (p=0.0001), furthermore the wild-placebo injected group compared to the APPxPSl-apape injected group show significant different (p=0.003). We also found significant difference between the transgenic-placebo administered and the APPxPSl+apape injected animals (p=0.021).
Table 1. General structure of the novel peptides. The table lists the possible moieties certain positions of the novel peptides.
Where X= acyl group; Y= organic functional group; Al, A2, A3, A4 and A5 are amino acids (coded and non coded, L or D) or acyl group
Detailed description of the invention
Peptide structures of the present invention were designed on the basis of computer performed analysis of the common binding sequences of Αβ 1-42 binding proteins (Verdier et al. J. Neurochem. 94, 617-28, 2005). (Table 4). The common Αβ-binding sequences of these proteins revealed by proteomic methods are very similar, containing mainly hydrophobic amino acids, proline and airtinodicarboxylic acids. Hence proline residues were incorporated in different part of the molecule since it is known to have greater β-breaking potential than the other proteinogenic amino acids (Chou and Fasman, Annu Rev Biochem 47: 251-276, 1978). Moreover, incorporation of proline into short peptides homologous to Αβ resulted in nonamyloidogenic analogues (Soto et al. Biochem Biophys Res Commun 226(3): 672- 680, 1996) . Peptides replacing L-amino acids by their D counterparts were also designed since the D-amino acids are more resistant to proteases and mostly non-immunogenic (Poduslo et al. J Neurobiol 39(3): 371-382, 2003: Dintzis et al . Proteins 16(3): 306-308, 1993). To improve the properties of the peptides, suitable chemical modifications, i.e. N- and C- terminal modifications and incorporation of peptidomimetics have been performed (Table 1 and 2) . Due to the complexity of the issue, it is clear that multidisciplinary approaches are needed, including methods to detect the early effects (synaptic activity, long-term potentiation (LTP) and late effects (cytotoxic effects) of Αβ on a cellular level combined with analysis for AD-linked pathophysiology (MTT test) and cognition assays to evaluate the progression of the disease and develop effective treatments.
The soluble forms of neurotoxic/synaptotoxic β-amyloid peptides (Αβ 1-42 oligomers and protofibrils) have no definite
conformations, only some secondary structural elements (e.g. β- sheet parts) . The Αβ-peptides belong to the family of intrinsically disordered proteins (IDP) . These proteins interact non-specifically with a big number of important cellular proteins causing neuronal dysfunction. The new class of compounds acts as β-amyloid structure modifying agents. They bind to the soluble, toxic Αβ oligomers and protofibrils via a salt bridge and apolar interaction (s) , and convert them to nontoxic conformation. Afterwards, these peptides initiate aggregation to big, non-toxic Αβ-aggregates . Simultaneously, the novel class of compounds stimulates the formation of dendrites and improves communication between the neurons.
The present invention relates to peptides and peptidomimetics of the following formula:
X-A Aa-A s-Y
Where X=acyl group; Y= organic functional group; A1-A5 are amino acids (coded and non coded, R or S) or acyl group (see Table 1) .
The present invention also relates to amino acid sequences, which are sequentially analogous to the described sequences and the biological activity of which is also analogous when
compared to the described sequences. A person skilled in the art finds it obvious that certain side change modifications or amino acid replacements can be performed without altering the biological function of the peptide in question. Such
modifications may be based on the relative similarity of the amino acid side chains, for example on similarities in size, charge, hydrophobicity, hydrophilicity, etc. The aim of such changes may be to increase the stability of the peptide against
enzymatic decomposition or to improve certain pharmacokinetic parameters .
The scope of protection of the present invention also includes peptides, in which elements ensuring detectability (e.g.
fluorescent group, radioactive atom, etc.) are integrated.
Furthermore, the scope of protection of the present invention also includes peptides, which contain a few further amino acids at their N-terminal, C-terminal, or both ends, if these further amino acids do not have a significant influence on the
biological activity of the original sequence. The aim of such further amino acids positioned at the ends may be to facilitate immobilisation, ensure the possibility of linking to other reagents, influence solubility, absorption and other
characteristics .
We used the IUPAC recommendations to mark the amino acid side chains in the given sequences (Nomenclature of -Amino Acids, Recommendations, 1974 - Biochemistry, 14(2), 1975).
The present invention also relates to the pharmaceutically acceptable salts of the peptides with general formula (I) according to the invention. By this we mean salts, which, during contact with human or animal tissues, do not result in an unnecessary degree of toxicity, irritation, allergic symptoms or similar phenomena. As non-restrictive examples of acid addition salts the following are mentioned: acetate, citrate, aspartate, benzoate, benzene sulphonate, butyrate, digluconate, hemisulphate, fumarate, hydrochloride,
hydrobromide, hydroiodide, lactate, maleate, methane
sulphonate, oxalate, propionate, succinate, tartarate,
phosphate, glutamate. As non-restrictive examples of base addition salts, salts based on the following are mentioned:
alkali metals and alkaline earth metals (lithium, potassium, sodium, calcium, magnesium, aluminium) , quaternary ammonium salts, amine cations (methylamine, ethylamine, diethylamine, etc. ) .
The peptides according to the invention can be used in
pharmaceutical preparations, where one or more additives are needed to reach the appropriate biological effect. Such preparations may be pharmaceutical preparations combined for example with matrices ensuring controlled active substance release, widely known by a person skilled in the art. Generally matrices ensuring controlled active substance release are polymers, which, when entering the appropriate tissue (e.g. blood plasma) decompose for example in the course of enzymatic or acid-base hydrolysis (e.g. polylactide, polyglycolide) .
In the pharmaceutical preparations according to the invention other state-of-the-art additives can also be used, such as diluents, fillers, pH regulators, substances promoting
dissolution, colour additives, antioxidants, preservatives, isotonic agents, etc. These are state-of-the-art additives.
Preferably, the pharmaceutical preparations according to the invention can be entered in the organism via parenteral
(intravenous, intramuscular, subcutaneous, etc.)
administration. Taking this into consideration, favourable pharmaceutical compositions may be aqueous or non-aqueous solutions, dispersions, suspensions, emulsions, or solid (e.g. powdered) preparations, which can be transformed into one of the above fluids directly before use. In such fluids suitable vehicles, carriers, diluents or solvents may be for example water, ethanol, different polyols (e.g. glycerine, propylene glycol, polyethylene glycols and similar substances) ,
carboxymethyl cellulose, different (vegetable) oils, organic esters, and mixtures of all these substances.
The favourable forms of packaging of the pharmaceutical
preparations according to the invention include for example tablets, powders, granules, suppositories, injections, syrups, etc .
The administered dose depends on the type of the given disease, the patient's sex, age, weight, and on the severity of the disease. In the case of oral administration the favourable daily dose may vary for example between 0.01 mg and 1 g, in the case of parenteral administration (e.g. a preparation
administered intravenously) the favourable daily dose may vary for example between 0.001 mg and 100 mg in respect of the active agent.
Furthermore, the pharmaceutical preparations can also be used in state-of-the-art liposomes or microcapsules. The peptides according to the invention can also be entered in the target organism by state-of-the-art means of gene therapy.
The peptides according to the invention can be used first of all in the medical treatment of diseases, in the case of which the inhibition of aggregation of β-amyloid to toxic species is beneficial, wherein the target β-amyloid peptide comprises a β- sheet sequence susceptible to further aggregation up to
fibrillation. Consequently the present invention also relates to the use of peptides in the manufacture of drugs for the treatment of such diseases. As it has been explained above in detail, such diseases are first of all certain
neurodegenerative diseases and type 2 diabetes mellitus, especially the following diseases: Alzheimer's and Parkinson's disease .
To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention.
As used herein, 'aggregation' means the association of peptide moieties, whether the resulting structure is regular or irregular, stable or unstable or with ordered or disordered native states. Such association can occur through intermolecular interactions, hydrophobic interactions, hydrogen bonds, van der aals forces, ionic bonds or any force or substance that can result in the collection or association together of two or more peptides or peptide regions. As used herein, "aggregation" encompasses, for example, fibrillation, or the formation of fibrils.
'Amyloid' describes various types of protein aggregations that share specific traits when examined microscopically. The name amyloid comes from the early mistaken identification of the substance as starch (amylum in Latin) , based on crude iodine- staining techniques. Amyloid is typically identified by a change in the fluorescence intensity of planar aromatic dyes such as Thioflavin T or Congo Red. This is generally attributed to the environmental change as these dyes intercalate between beta-strands. The deposits are characterized by the abnormal folding of amyloidogenic protein from a normal secondary structure (often an a-helix, but can also be a random coil) into a pathological β-sheet structure, which permits aggregation into insoluble fibrils. Ultrastructurally, amyloid fibrils are made up of a helical configuration of two protofilaments . These deposits are characteristically resistant to protease digestion. Amyloid polymerization is generally sequence-sensitive, that is, causing mutations in the sequence can prevent self-assembly, especially if the mutation is a
beta-sheet breaker, such as proline. For example, humans produce an amyloidogenic peptide associated with type II diabetes, but in rodentia, a proline is substituted in a critical location and amyloidogenesis does not occur. Approximately 25 different proteins are known that can form amyloid in humans.
The term 'amyloidosis' refers to a disease or disorder associated with abnormal protein folding into amyloid or amyloid-like fibrillar deposits in which the abnormally folded proteins in the deposits have a characteristic pathological beta-sheet structure.
As used herein, the terms ' β-amyloid peptide', 'amyloid β peptide' or Άβ peptide' refer to a human amyloidogenic peptide that derives from APP by proteolytic cleavage. Various pathogenic forms of Αβ peptides include Αβ 1-42, Αβ 1-40, Αβ 5- 42, etc. (the numbers following Αβ refer to the starting and ending positions in the amino acid sequence) . The amino acid sequence of the human Αβ 1-42 peptide is the following:
DAEFRHDSGYEVHHNKLVFFAEDVGSNKGAIIGLMVGGVVIA. (SEQ ID NO 66) Mutant human Αβ 1-42 peptides are also known in some familial ADs (like e.g. Swedish mutation). Unless otherwise stated, under the term 'β-amyloid peptide' these mutations are also meant.
As used herein, 'protein folding' is the physical process by which a polypeptide folds into its characteristic and functional three-dimensional structure from random coil. The correct three-dimensional structure is essential for biological activity. Failure to fold into native structure produces inactive proteins that are usually toxic. Several neurodegenerative diseases are believed to result from the accumulation of amyloid fibrils formed by misfolded proteins.
As used herein, 'intrinsically disordered proteins' (IDPs) are proteins which lack stable tertiary and/or secondary structure in solution yet fulfill key biological functions.
A protein may undergo reversible structural changes in performing its biological function. The alternative structures of the same protein are referred to as different
'conformations' and transitions between them are called
'conformational changes' . As used herein, the term 'peptide' , when used in reference to an agent that binds amyloid or amyloid-like deposits refers to a peptidic compound made up of 2, 3, 4, 5, 6, or more amino acid residues in length, and also includes amino acid residues with D or L stereochemistry. A peptide' as used in this context specifically excludes an antibody or an antigen-binding fragment (e.g. an Fab) of an antibody, and also an amyloidogenic sequence, such as Αβ 1-40, which aggregates with other like molecules and forms a β-sheet structure. As used herein, 'peptidomimetic' , also referred to as 'peptide mimetic' , means any compound containing amino acid residues, whether D- or L-, whether natural or non-naturally occurring, and it can also comprise non-amino acid moieties. A 'peptidomimetic' is designed to mimic the biological action (s) of a natural mimicked peptide, including, for example, those designed to mimic the structure and/or binding activity (such as, for example, hydrogen bonds and hydrophobic packing interactions) of the peptides according to the methods disclosed herein.
As used herein, the term 'pentapeptide' refers to a compound of five amino acids, modified amino acids or amino acid substitutes. For example, the compound apape (SEQ ID NO: 51) is
a pentapeptide consisting of D-Ala, D-Pro, D-Ala, D-Pro and D- Ala-amide .
As used herein, the term 'resistant to. rotease digestion' or 'enzymatically resistant' entails that a given folded form of a polypeptide is cleaved at least 25% less than an alternatively folded form of that polypeptide when both forms are contacted with a similar amount of a given protease enzyme under the same conditions. Since the terms is used for peptides and peptidomimetics for reducing the toxicity of amyloid or amyloid-like deposits, a peptidomimetic is 'resistant to protease cleavage' if it is cleaved at least 10% less (and preferably 20, 30, 40, 50, 60, 70, 80, 90 or even 100% less) by a given amount of a given protease, relative to the cleavage of a corresponding peptide under like conditions.
As used herein, the term ^reduce' or ^inhibits' refers to at least a 10% decrease of the parameter being measured in the presence of an agent relative to the absence of that agent. For example, 'reducing neurotoxicity' means inhibiting the toxic effect of a composition or environment against neural cells or tissue by at least 10% relative to cells or tissue not treated in a manner to reduce such toxic effect.
As used herein, the term 'neurotoxicity' describes the ability of a substance, condition or state to impair, or even kill the functioning of a neural tissue or cell.
As used herein, 'binding' encompasses physical association of one molecule with another. Binding can be both covalent and non-covalent interatomic and intermolecular interaction, whether long lasting or transient. Examples include, without limitation, ionic bonds, hydrophobic interactions, hydrogen
bonds, Van der Waals forces and dipole-dipole bonds. As used herein, the term 'neuronal cell' refers to a cell of the central nervous system, including, but not limited to a neuron and a glia.
As used herein, 'screening test' encompasses tests conducted to determine if candidate inhibitory peptides are effective in disrupting Αβ toxicity. Examples of such screening tests are described herein. However, a person of ordinary skill would recognize that other screening tests can be employed without departing from the spirit and scope of the invention.
Examples Below the present invention is described in detail on the basis of examples, which, however, should not be regarded as examples to which the invention is restricted.
Until recently, the synthetic commercial Αβ 1-42 samples were not homogenous as for aggregation grade and water solubility. As a consequence, the biological studies performed by these peptides were not always reproducible. We and others have shown that Αβ assemblies with defined aggregation grade (oligomers and fibrils) can be reproducibly prepared from iso-Αβ 1-42 under specific conditions (Bozso et al. Peptides 31: 248-256, 2010) . This will greatly facilitate studies aiming at
understanding the molecular basis of AD.
Example 1: Design of small peptides inhibiting amyloid toxicity
Oligomerization and aggregation of some polypeptides and proteins (β-amyloid, -synuclein, huntingtin, prion protein) appears to be a key factor in the neurodegeneration process in a group of diseases (e.g. AD) . The soluble forms of
neurotoxic/synaptotoxic β-amyloid peptides (Αβ-1-42 oligomers and protofibrils) have no definite conformations, only some secondary structural elements (e.g. β-sheet parts) . The Αβ- peptides belong to the family of intrinsically disordered proteins (IDP) . These proteins interact non-specifically with a big number of important cellular proteins causing neuronal dysfunction. Our novel neuroprotective compounds (see Table 2.) bind to the soluble, toxic Αβ oligomers and protofibrils via a salt bridge and apolar interaction (s) . The novel class of compounds acts as β-amyloid structure modifying agents. These novel compounds convert the intrinsically disordered Αβ- peptides to nontoxic conformation, and then initiate their aggregation to big, non-toxic Αβ-aggregates . Simultaneously, the novel class of compounds stimulates the formation of dendrites and improves communication between the neurons, and thereby decreases the detrimental effect of Αβ-peptides in the brain .
1. Peptide synthesis
Materials
All N-terminally protected amino acids were purchased from Orpegen (Heidelberg, Germany) Bachem (Bubendorf, Switzerland) and GL Biochem (Shanghai, China) . DCC, HOBt and MBHAxHCl resin were from GL Biochem (Shanghai, China) . Boc-Ala-PAM resin was from Bachem (Bubendorf, Switzerland) . Boc-D-Gln-Merrifield resin, Boc-D-Asn-Merrifield resin, Boc-D-Glu (Bzl) -Merrifield resin and EDC*HC1 were from IRIS Biotech GmbH (Marktredwitz, Germany) . Solvents and DIPEA were obtained from Sigma-Aldrich. HPLC grade TFA was ordered from Pierce (Rockford, IL, USA).
A) β-amyloid peptides
Controlled in situ preparation of Αβ 1-42 oligomers from the isopeptide 'ϊεο-Αβ 1-42' was performed as published (Bozso et al, . Peptides 31: 248-256, 2010). B) Synthesis of the novel inbibitory peptides and
peptidomimetics
Boc-chemistry protocol
a. Protocol for the following peptides: EPAPA-NH2, EPPPA-NH2, APAPE-NH2, APPPE-NH2 , epapa-NH2, epppa-NH2, apape-NH2, apppe- NH2, EPAP-NH2, EPPP-NH2 , RPAPA-NH2, KPAPA-NH2, RPPPA-NH2 , KPPPA-NH2, pape-NH2, pppe-NH2, DPAPA-NH2, Succinyl-PAPA-NH2 , Propionyl-PAPA-NH2, -Ala-PAPA-NH2 , Iminodiacetyl-PAPA-NH2, E- Sar-APA-NH2, EPA-Sar-A-NH2 , E-Pip-APA-NH2 , EPA-Pip-A-NH2 , E- Sar-A-Sar-A-NH2, apapd-NH2, apapq-NH2, apapn-NH2, Propionyl- pape-NH2, Propionyl-papq-NH2 , apGpe-NH2, ap-N-Me-ala-pe-NH2, a- tic-ape-NH2, apa-tic-e-NH2 , ap-tic-pe-NH2 , a-Sar-ape-NH2 , apa- Sar-e-NH2, a-pip-ape-NH2, apa-pip-e-NH2, Gpape-NH2 , (N-Me-ala) - pape-NH2, ap-Aib-pe-NH2 , Aib-pape-NH2 , apap-NH2, APEPA-NH2, ape-NH2, Ac-ape-NH2, GABA-pe-NH2.
Peptides were synthesized on BHAxHCl resin. The resin was swollen in DCM then neutralized with 5% DIPEA/DCM solution (2x1 min) . After neutralization the resin was washed three times with DCM. Four-fold excess of Na-Boc protected amino acids were activated with DCC/HOBt in DCM/DMF (1:1) then the resin was incubated in this mixture for 3 hours. The resin was washed twice with DMF, DCM and methanol, it was partially dried and the coupling was monitored with qualitative ninhydrin test. If the ninhydrin test indicated incomplete acylation the coupling step was repeated. The resin was resuspended in DCM, then the Boc-protecting group was removed with 50% TFA/DCM (5+25 min) . The peptide-resin was washed 3x with DCM then neutralized as detailed above and a new cycle was started.
The peptide was cleaved from the resin with HF (cleavage cocktail: 10 mL HF, 0.8 mL dimethyl-sulfide and 0.2 mL anisole for 1 g of peptide-resin, 0 °C, 45 min) . The crude peptide was precipitated with diethyl-ether , dissolved in 50% ACN/water and lyophilized. b. Protocol for the following peptides: EPAPA, EPPPA, apapq, apapn, apape. Peptides were synthesized on the appropriate resin, depending on the C-terminal amino acid (Boc-Ala-PAM resin, Boc-D-Gln- Merrifield resin, Boc-D-Asn-Merrifield resin, Boc-D-Glu (Bzl ) - Merrifield resin) . The resin was swollen in DCM, and then the Boc protecting group was removed as detailed above. Neutralization, coupling and cleavage from the resin was performed following the procedures detailed in section a.
Fmoc-chemistry protocol
PPPA-NH2, PAPA-NH2 , AC-EPAP-NH2, EPA-NH2, AC-EPA-NH2, EPP-NH2, DPA-NH2, DP-NH2, Succinyl-PA-NH2 , Succinyl-pa-NH2 and Glp-Asp- NH2 were synthesized with Fmoc-chemistry.
Peptides were synthesized on Fmoc-Rink amide resin. The resin was swollen in DCM, the washed with DMF and Fmoc protecting group was removed by treating it with 20% piperidine/DMF (5+15 min). The resin was washed with DMF five-times. Three-fold excess of Na-Fmoc protected amino acids were activated with DCC/HOBt in DCM/DMF (1:1) then the resin was incubated in this mixture for 3 hours. The resin was washed twice with DMF, DCM and methanol, it was partially dried and the coupling was monitored with qualitative ninhydrin test. If the ninhydrin test indicated incomplete acylation the coupling step was repeated. The resin was resuspended in DMF, and the Fmoc group was removed as detailed above. Cycles were repeated until the required sequence was obtained. The peptide was cleaved from
the resin using a mixture of TFA (95%) , water (2%) , triisopropyl-silane (1.5%) and dithiothreitol (1.5%). The cleavage was performed on 0 °C for 15 min, then at room temperature for 2 hours 45 min. The crude peptide was precipitated with diethyl-ether, dissolved in 50% ACN/water and lyophilized.
Synthesis of Glp-Gly Glp, Gly-OtBu and EDC*HC1 (1 mmol of each) were mixed in 15 mL NaHC03 (100 mM) for 6 h. The mixture was then extracted with ethyl-acetate (3x) . Ethyl-acetate was evaporated and the resulting oil was mixed with 50% TFA/DCM for 30 min. TFA and DCM was evaporated and the oil was purified on HPLC.
Purification
Peptides were analyzed and purified using RP-HPLC. 0.1 % TFA in d.i. water and 80% ACN, 0.1% TFA in d.i. water was used as eluent A and eluent B, respectively. Analytical analysis was done on a Hewlett-Packard Agilent 1100 Series HPLC apparatus using a Luna C18 column (100 A, 5 μιη, 250x4, 60 mm, Phenomenex) , the flow rate was 1.2 mL/min and the gradient was as it is indicated in Table 2. Preparative chromatography was done on a Shimadzu HPLC apparatus equipped with a Luna C18 column (100 A, 10 m, 250x21.2 mm, Phenomenex) with a flow rate of 4 mL/min. The gradient was 0-30% eluent B in eluent A over 60 min.
Mass spectrometry
Mass spectrometry measurements were done on a FinniganMat TSQ 7000 mass spectrometer in ESI-MS mode.
2. Transmission electron microscopy (TEM)
Oligomeric and fibrillar structures of Αβ 1-42 were prepared from iso-Αβ 1-42 (75 μΜ) as published (Bozso et al. Peptides 31: 248-256, 2010). Ten ul droplets of Αβ 1-42 solution (75 μΜ) with or without apape (SEQ ID NO: 51) (1:5 molar ratios) were placed on formvar-carbon coated 400 mesh copper grids (Electron Microscopy Sciences, Washington, PA, USA) and stained negatively with uranyl acetate. The aggregates were characterized by transmission electron microscopy with a Philips CM 10 transmission electron microscope (FEI Company, Hillsboro, Oregon, USA) operating at 100 kV. Images were taken by a Megaview II Soft Imaging System at magnifications of x
46,000 and x 64,000, and analyzed by an Analysis® 3.2 software package (Soft Imaging System GmbH, Miinster, Germany) .
3. Dynamic light scattering (DLS)
The following solutions were prepared in PBS, and placed in a low volume sizing cuvette: Αβ 1-42 (50 μΜ) , Αβ 1-42. (50 μΜ) + apape (SEQ ID NO 51) (250 μΜ) , Αβ 1-42 (50 μΜ) + Cys-Gly7-amide (250 μΜ) . Size distribution was measured at 25 °C with a Malvern Zetasizer Nano ZS Instrument (Malvern Instruments Ltd. Worcestershire, UK) equipped with a He-Ne laser (633 nm) applying the Non-Invasive Back Scatter (NIBS®) technology, which means detection of the scattered light at an angle of 173°. The change in size distribution was followed for 22 hrs . For one single measurement, correlation function and distribution of the apparent hydrodynamic diameter (dh) over the scattered intensity of the particles were determined on the basis of 14 scans. The translational diffusion coefficients were obtained from the measured autocorrelation functions using a fitting algorithm built in the software package Dispersion Technology Software 5.1 (Malvern Instruments Ltd. Worcestershire, UK) .
4. Electronic circular dichroism (ECD) spectroscopy
ECD spectra of the Αβ 1-42, apape-NH2 and their mixture were recorded on a Jasco (Tokyo, Japan) J815 spectropolarimeter equipped with a Peltier temperature controller using a 1 or 2 mm path length quartz cell. Peptide samples were dissolved in HCBS buffer. The concentration of Αβ 1-42 was 12.5 μΜ, while the concentration of apape-NH2 was 62.5 μΜ. Spectra of peptide solutions in the 200-250 nm wavelength region were recorded at 37 °C and 100 nm/s scan speed over a one week period at the following time points: 0 min, 10 min, 20 min, 30 min, 1 h, 3 h, 6 h, 24 h, 48 h, 72 h, 168 h. Spectra presented here are accumulations of 10 scans and the corresponding solvent spectra similarly recorded were subtracted.
5. Computational Binding Study
The fibril model is based on the NMR structure published by Liihrs et a. (PNAS 102/48: 17342-17347, 2005) and contains eight Αβ 1-42 monomer units. The missing residues at the N-terminal part were completed assuming a β-structure. The accomplished structure was embedded into explicit water (TIP3P type) environment and 4 ns long molecular dynamics simulation was performed with the help of the AMBER8 program package (Case et al. AMBER 8, University of California, San Francisco, 2004) applying the FF03 forcefield with its own atomic charges. To map the possible binding positions of the small molecules onto the Αβ 1-42 fibril surface, the ^blind docking' procedure (Hetenyi and van der Spoel, Protein Science 11:1729-1737, 2002) was applied using the Autodock program (Morris et al. J. Comput. Chem. 19: 1639-1662, 1998). Ligand set was re-docked onto the possible binding regions with better grid-map, and those molecules were considered as binding-ones which had large
binding free energy (BFE) value in all the regions. Two scores were considered for every peptide: the best BFE value of the docked positions on one hand and the average of the best 10 poses according to the BFE value of a given ligand on the other hand. Taking the geometries from the docking calculation, 1 ns explicit water simulations were performed for selected complexes (fibril model + ligand) and BFEs were calculated with the molecular mechanics-generalized Born surface area (MM-GBSA) method (Srinavasan et al. J. Am. Chem. Soc. 120 9401-9409, 1998).
6. Conformational Analyses
Replica-Exchange Molecular Dynamics (REMD) calculations with 24 trajectories were performed for each molecule between 280 - 430 K using explicit water (TIP3P) environment. 50 ns long simulations were accomplished in all cases by the GROMACS package (Hess et al. J. Chem. Theory Comput . 4: 435-447, 2008) applying the amber99sb forcefield (http://ambermd.org). Taking the trajectory at the lowest temperature, cluster analyses were performed at the 10 -50 ns interval by the ptraj program from the AmberTools package (http://ambermd.org). 4000 snapshots were selected from the trajectory in each case, and the ''average linkage' method was applied with two cut-off (epsilon) values: ε=1.0 for the clusterization on the main-chain atoms, and ε =1.5 values for the clusterization on the heavy atoms.
Conclusions Based on computer simulation to find common sequences in amyloid binding proteins (Table 1), 72 novel peptides were designed of which 65 are discussed within the frame of the present invention. The MS and HPLC analytical parameters of the novel peptides are summarized in Table 2. The physico-chemical
parameters of Αβ oligomers and fibrils in the absence and in the presence of the novel peptides were determined. The morphology of the aggregates can be seen on the TEM images
(Fig. 2) . It was observed that the apape peptide (SEQ ID NO: 51) (in 1:5 molar ratios) promoted the formation of the fibrillar aggregates, which formed already after 4 h of incubation, while the control sample contained only protofibrils and high-n oligomers. The presence of fibrillar aggregates could be observed in both samples after 24 h. These observations, together with the DLS data, indicate that apape
(SEQ ID NO: 51) acts as an aggregation promoter instead of an aggregation inhibitor of the beta amyloid.
ECD spectra of the Αβ 1-42 shows a strong minimum at 200 nm and another peak at 215 nm, indicative of a mixture of random and β-sheet structures even right after the dissolution of the peptide sample (Fig. 3A) . apape-NH2 displayed a random structure by itself and spectra recorded in later time points were not different from the one acquired immediately after dissolution of the sample (Fig. 3B) . This suggests that no major structural change of the pure peptide takes place during the one week period. Spectra recorded for the 1:5 molar ratio mixture of Αβ 1-42 and apape-NH2 appears to be a simple combination of the spectra of the pure component peptides. The aggregation iso-amyloid β 1-42 in the presence of apape-NH2 appears to be less gradual as compared to the case of pure iso- amyloid β1-42. A major structural change was observed after 6 hours. However, after the initial lagging period, structural transformation comes to completion similarly to that observed in the absence of apape-NH2. Difference spectra obtained by subtracting the corresponding pure apape-NH2 spectra from those of the Αβ 1-42 and apape-NH2 mixture are markedly different from those recorded for pure Αβ 1-42. The most conspicuous difference is the blueshift of the 215 minima, which indicates
a small-scale structural change (Fig. 3C-D) . Such structural change may take place as a result of an intermolecular interaction between the two component peptides. The presence of apape-NH2 may slightly affect the aggregation kinetics of Αβ 1- 42 as indicated by spectra of Fig. 3D. However, this difference in the aggregation behaviour is less apparent in the difference spectra shown on Figs. 3C and D.
It was revealed from the computational binding simulation (docking studies augmented with MM-GBSA method (Fig. 4) that there is an elongated, poly-proline II helix-like backbone structure which can be found in all cases except the xpape' peptide which seems to be too short to form this structure (Fig. 4). However, an elongated conformation is also typical even for the xpape' peptide.
Example 2. In vitro studies of the neuroprotective effect of the peptides NaCl, KC1, CaC12, MgCl2, HEPES, NaHC03, D-Glucose, MIT and 96- well plates (Costar) were purchased from Sigma-Aldrich (Hungary) . The ExViS mini-chamber system was from our institute. The animal protocols applied in this study had been approved by the National Institute of Health and by the University of Szeged; permission number: 1-02442/001/2006.
Preparation and treatment of acute hippocampal slices
A slightly modified version of the method reported (Datki et al. Brain Res Bull. 74/1-3, 183-7, 2007) was used in our slice viability experiments. After anesthesia with chloral hydrate (0.4g/kg), 10 ± 1 -weeks-old male istar rats were decapitated and the whole heads (without scalp-leather) were put in ice- cold distilled water for 1 min. The brains were quickly removed
and immersed in H-ACSF/1 (preparation solution) with very low Ca2+ and with elevated Mg2+ at 4 °C (Ref . 4) . The composition of this preparation solution (in mM) : NaCl 122, KC1 3, CaC12 0.3, MgC12 3.7, NaHC03 25, HEPES 5.0, D-glucose 10.0, pH=7.4. Brain slices (400 μπι thick) were prepared from the hippocampus with a Mcllwain tissue chopper at 4 °C in ice cold H-ACSF/1 solution followed by taking photos of them (for measuring slice area) . The slices (with an area of approximately 9 mm2) were rapidly transferred into the ExViS mini-chamber (maximum 10 slice in 1 ml) for conditioning (30 min) in the carboxygenated (02:C02= 95 : 5%) preparation solution at room temperature (24 °C) . After resting (30 min) in the carboxygenated H-ACSF/1 solution at room temperature, the brain slices were transferred from the mini-chamber into the plastic Petri dish with cut-off pipettes (type 200 μΐ) in glucose- and carboxigenated-free H- ACSF/2 (2 ml/Petri dish) for one hour. The composition of this H-ACSF/2 (in mM) : NaCl 132, KC1 3.0, CaC12 2.0, MgC12 2.0, NaHC03 25, HEPES 5.0, pH=7.4. The Petri dish was stirred continuously at 370 rpm (modified BIOSAN TS-100 thermo shaker) . After resting/treated in glucose- and oxygen-free H-ACSF/2, the Petri dish content (supernatant) was changed to the normal H- ACSF/1 solution (2 ml/Peri dish) . The slices were rapidly transferred into the ExViS mini-chamber (maximum 10 slice in 1 ml) for treating with Αβ 1-42 (50 μΐ stock solution into 950 μΐ per chamber; 20 μΜ Αβ 1-42 in final concentration) . Before each slice viability assay, the stock solution of Αβ peptide (0.4 mM) was freshly prepared (and stored for maximum 10 min) in distilled water (pH=5) . The peptidomimetics were used in 40 μΜ and 100 μΜ final concentration, alone or together with Αβ 1-42 (mixed in DW before slice treatment) . After treating the slices with Αβ 1-42 and/or peptidomimetics for 4 hours, 0.1 ml MTT (stock solution 5 mg/ml H-ACSF/1) was added to the wells in which they were rested for 15 min without carboxigenation. To stop the reduction of the MTT to formazane crystals, the slices
were transferred from H-ACSF/1 to DMSO and incubated for 30 min (50 μΐ DMSO/one slice) . The optical density (OD) of the dissolved formazane was measured at 550 and 620 nm. The following formula: (OD550 - OD620)/area of slice (mm2) = 100% in control (Αβ 1-42 untreated slices) was used for data synchronization.
Conclusions Table 3 summarizes the results of the MTT-assay of several novel peptides in two concentrations. It can be seen that among the peptides studied pape-NH2 has the least protective effect against and all the other peptides studied almost completely eliminated the toxic effect of Αβ . On the basis of these results, we have selected apape (SEQ ID NO: 51) as the leading compound for further biological experiments.
Example 3. In vivo studies using the experimental rat model for electrophysiology
Αβ 1-42 preparation
The synthesized Αβ 1-42 was dissolved in 1,1,1,3,3,3- hexafluoro-2-propanol (HFIP) and incubated overnight at ambient temperature. After removal of the HFIP in vacuo, the peptide was dissolved in d.i. water and incubated at 37 °C for 3 days. Fibrils were collected by centrifugation at 10 000 x g for 15 min and the pellet was washed with d.i. water and lyophilized. Prior to use, the peptide was freshly dissolved in pH 6.4 saline to a final concentration of 5x10-5 M, gently sonicated for 15 min in order to facilitate the homogenization of the sample, and used in the biological experiments.
Extracellular recordings and microiontophoresis
Extracellular single-unit recordings were performed in the rat hippocampus (Wistar male 250 to 330 g) after chloral hydrate anesthesia (intraperitonial, i.p. 0.4 g/kg initial dose, supplementary doses as required) . The animals were handled and surgery performed in accordance with the European Communities Council Directives (86/609/ECC) and the Hungarian Act for the Protection of Animals in Research (XXVIII. tv. Section 32). Ethical approvement number was 1-74-13/2010. All efforts were made to minimize pain and reduce the number of animals used. The head of each animal was mounted in a stereotaxic frame, the skull was opened above the hippocampus (a-p:-3.8 mm from bregma; lat: ±2 mm from the midline on either side), and the dura mater was carefully removed. Following a 1 hour recovery period, single-unit activity of the CAl hippocampal neurons was recorded extracellularly between depths of 2 and 3 mm by means of a low-impedance (< 1 ΜΩ) 7 μπι carbon fiber-containing multibarrel microelectrode ( ation Scientific, Minneapolis, N, USA) , and drugs were delivered from the surrounding capillary barrels. Action potentials were amplified by an ExAmp-20KB extracellular amplifier (Kation Scientific) and monitored with an oscilloscope. The filter bandpass frequencies were 300 to 8000 Hz. A window discriminator (WD-2, Dagan Corporation, MN, USA) was used for spike discrimination. The amplified signals were sampled and digitalized at 50 kHz. The number of action potentials per second was counted by the computer and peristimulus time histograms were calculated and displayed in line. Iontophoretic drug delivery and experimental data collection were governed by a PCI-1200 multifunction instrument control and data acquisition board (National Instruments, Austin, TX, USA) placed in a computer programmed in LabVIEW 6, and by iontophoretic pumps (Minion-16 and BAB-350, Kation Scientific) . A multibarrel electrode affixed to the recording electrode was used for iontophoretic ejection of the following
drugs: (a) 100 mM NMDANa (Sigma-Aldrich, Budapest, Hungary) in 100 mM NaCl (pH 8.0); (b) 5 χ 10-5 M Αβ1-42 and (c) 2.5 χ 10-4 M peptides dissolved in saline (pH 6.4); (d) a mixture containing Αβ1-42 (5 χ 10-5 M) and the peptides to be studied (2.5 x 10-4 M) stored for 1 h, and (e) to mark the position of the electrode, 4% Pontamine Sky Blue (BDH Chemicals, Poole, England) in 100 mM sodium acetate. The Αβ 1-42 was ultrasonicated for 15 min prior to use. Neurons were excited by repetitive iontophoresis of NMDA at 1 min intervals for 5 s by applying negative iontophoretic currents ranging from 5 to 100 nA and the ejection current was selected so that the maximum firing rate fell between 30 and 80 spikes/s. Retaining current of the opposite direction in the range 2-21 nA was used. The peristimulus time histograms of the neurons were recorded. After establishment of a stable control, the peptides to be tested were co-iontophorized for 3 min at +100 nA, followed by Αβ 1-42 for 1 min at -0.5 μΑ. In the second part of the experimental procedure, a mixture of Αβ 1-42 and a pentapeptide was ejected for 1 min at -0.5 μΑ. Recording sites were marked by the iontophoretic ejection of PSB at a negative current of 5 μΑ negative current for 10 min. At the end of each experiment, the animals were euthanized with an overdose of chloral hydrate. The brain was quickly removed and fixed in 4% paraformaldehyde. Brain sections (50 μιη thick) were counterstained with Neutral Red, and the PSB localization was verified according to the stereotaxic atlas of Paxinos and Watson (1986) . Statistical evaluation was performed using the total number of spikes evoked during each epoch of excitation by the iontophoretic application of NMDA. Differences in magnitude between the different response epochs of a single cell were tested by comparing the total numbers of spikes per excitation
period by one-way A OVA followed by the Dunett' s post hoc analysis. The mean of pre-Αβ 1-42 NMDA-evoked responses was taken as 100% in every experiment. The maximum response rate of post-Αβ 1-42 was given as percentage of the control. Data were pooled for statistical analysis. Shown are means ± SEM. Statistical significance was set at p <0.05.
Intraperitoneal administration of peptides and in vivo single- unit recordings
Extracellular single-unit recordings were obtained from 72 CA1 neurons from a total of 32 anesthetized rats. Pentapeptides were administered i.p. (0.5 mg/100 g) , and peristimulus histograms were then taken. The data from all 40-min intervals were pooled and means ± SEM of percentage values were calculated. The pre-Αβ 1-42 control firing rate was set between ~30-80 spike/sec. In that way, the rate of amyloid induced excitation was not dependent of the initial firing rate. The pre- Αβ 1-42 firing values were considered as 100% at each recording, and the maximum post Αβ 1-42 firing rates in % value were used for statistical evaluations.
Conclusion These studies indicated that the peptide apape protected against the NMDA response-enhancing effect of Αβ 1-42 between * 50-250 min after i.p. administration (Fig. 7) suggesting that apape may cross the blood brain barrier. Example . Behavior and learning studies in rat model
Morris water maze (M M) task prot
The maze consisted of a circular pool (diameter: 130 cm, height: 60 cm). The pool was filled to a depth of 40 cm with water (23±1 °C) containing milk. The pool was divided into four virtual quadrants. A circular glassy platform (diameter: 10 cm) was placed in the middle of one of the four quadrants of the pool. The location of the platform was the same during five days. The platform was submerged 1.5 cm below the water surface, so that it was invisible at water level. There was a black curtain around the pool. We placed different geometric shapes in all four directions on the curtain. The tank was placed in a dimly lit, soundproof test room.
The experiment lasted for five days. We used two different starting points. One of the two points was nearly the platform, the other one far from the location of the platform. The mice swam every day two times (two trials) and were placed into the water facing the wall of the pool. The time interval between each trial sessions was 30 seconds. The animals had 90 seconds to find the platform, and 15 seconds to stay on it. Those animals, which did not find the platform were gently guided and placed on it until 15 seconds. The animal was taken to its home cage and was allowed to dry up after the end of the two trials.
During each trial session, the time taken to find the hidden platform (latency) was recorded using a video camera-based Ethovision System (Noldus, Wageningen, Netherlands) . The total duration in arena (the time spent in the arena) was investigated on each day. Statistical analysis was performed with repeated measured analysis of variance (ANOVA) , and Fisher's LSD post hoc test.
Conclusion
Behavior and learning experiments proved the applicability of the novel peptides as neuroprotective agents in vivo (Fig. 8- 10) . Morris water maze experiments for studying the reference memory showed that the studied novel peptides and peptidomimetics significantly decrease the time for learning, and they also prevent the neurotoxic effect of Αβ 1-42 aggregates .
Example 5. Histological studies in rats Cresyl violet staining
The animals were anaesthetized with 5 % chloral hydrate (400 mg/bwkg) and perfused transcardially with physiological saline followed by 4% paraformaldehyde in phosphate buffer (0.2 M, pH 7.4). The brains were carefully removed from the skull, postfixed for 1 day in 4% paraformaldehyde, and then left for 2 days in phosphate-buffered saline containing 30% sucrose and 0.01% sodium azide at 4°C. Fifty i thick cross sections were cut and mounted onto gelatine-coated microscopy slides for Nissl staining. The slides were rinsed in 0.2 M PBS, and stained in 0.5% cresyl violet acetate for 1.5-2 minutes. After the staining procedure, the slides were rinsed again in PBS for 20-30 seconds. The slides were immersed consecutively in 70%, 80% and 95% ethanol followed by absolute alcohol and 99% butanol for 20-30 seconds. Finally, slides were placed in Hellendal staining jars containing xylene and mounted with DPX. The slides were scanned in a Zeiss MIRAX MIDI Slide Scanner (Carl Zeiss Inc., Germany). The left and right side of the hippocampus were annotated and the HistoQuant software (3D
Histech Kft . , Budapest, Hungary) was used to calculate the density of cells.
TAU immunohistochemistry
The animals were anaesthetized and perfused as above. Their brains were dissected and hippocampus isolated. Fifty μιη thick cross sections were cut in a cryostat. The sections were collected into wells containing PBS and processed for immunohistochemistry. Monoclonal mouse anti-human PHF-tau (paired helical filament tau), clone AT100 antibody (1:800 diluted) was used as the primer antibody (Thermo Scientific, Rockford, IL, U.S. A). Biotinylated anti mouse IgG (1:400 diluted) (Vector Laboratories, Inc. Burlingame) was used as a secondary antibody. Vectastain ABC kit (Vector Laboratories Inc.) was used to visualize the secondary antibody. The peroxidase reaction was developed with 3, 3 ' -diaminobenzidine tetrahydrochloride (DAB Sigma Aldrich Co. Ltd.) enhanced with 1% nickel-ammonium-sulphate. Finally, the f ee-floating slices were mounted on slides and digitally scanned in a Zeiss MIRAX MIDI Slide Scanner (Carl Zeiss Inc., Germany). The left and right side of the hippocampus were annotated and the HistoQuant software (3D Histech Kft., Budapest, Hungary) was used to calculate the number of tau immunopositive cells.
Conclusions
These studies showed that the novel peptides and peptidomimetics may stimulate the formation of dendrites and improve the communication between the neurons (Figs. 11-13).
epapa-NH2 483.2 482.53 0-25% / 25 min 12.28 epppa-NH2 509.2 508.57 0-25% / 25 min 12.35 apape-N¾ 483.1 482.53 5-25% / 20 min 7.24 apppe-N¾ 509.20 508.57 0-25% / 25 min 12.34
RPAPA-NH2 510.13 509.60 0-25% / 25 min 12.08
KPAPA-NH2 482.07 481.59 0-25% / 25 min 10.29
RPPPA-NHa 534.49
KPPPA-NH2 508.15 507.63 0-25% / 25 min 10.88
DPAPA-NH2 468.93 468.5 0-20% / 20 min 11.89 β-Ala-PAPA- NH2 425.05 424.49 0-20% / 20 min 11.88
E-Sar-APA-NH2 456.94 456.49 0-20% / 20 min 11.36
EPA-Sar-A-NH2 456.95 456.49 0-20% / 20 min 10.83
E-Pip-APA-NH2 497.0 496.56 0-20% / 20 min 16.81
EPA-Pip-A-NH2 496.82 496.56 10-30% / 20 min 11.02
E-Sar-A-Sar-A- NH2 431.35 430.45 0-20% / 20 min 9.68 apapq 482.53 0-20% / 20 min 11.74 apapd-N¾ 469.00 468.50 0-20% / 20 min 15.69 apapn 468.85 468.50 0-20% / 20 min 11.05 apapq-NH2 482.41 481.55 0-20% / 20 min 10.58 apapn-NH2 467.97 467.52 0-20% / 20 min 10.39 apape 484.01 483.51 0-20% / 20 min 13.38 apGpe-NH2 469.49 0-20% / 20 min 13.37 ap-N-Me-ala-pe- NH2 497.06 497.54 0-20% / 20 min 13.39 a-tic-ape-NH2 8.86
545.18 545.57 15-35% / 20 min 9.38 apa-tic-e-NH2 11.77
545.25 545.57 15-35% / 20 min 11.26 ap-tic-pe-NH2 10.28
571.26 571.61 10-30% / 20 min 11.29 a-Sar-ape-NH2 456.95 456.49 0-20% / 20 min 8.49 apa-Sar-e-NH2 456.92 456.49 0-20% / 20 min 11.81 a-pip-ape-NH2 497.21 496.56 5-25% / 20 min 12.20 apa-pip-e-NH2 497.29 496.56 10-30% / 20 min 6.59
Gpape NH2 468.94 469.49 0-20% / 20 min 13.30
(N-Me-ala)-
62 pape-NH2 496.99 497.54 0-20% / 20 min 10.34
63 ap-Aib-pe-NH2 497.24 497.54 10-30% / 20 min 12.39
64 Aib-pape-NH2 497.24 497.54 0-20% / 20 min 6.75
65 APEPA-NH2 483.01 482.53 0-20% / 20 min 7.50
Table 2. MS and HPLC analytical parameters of the novel peptides
Table 3 . The neuroprotective effect of the novel peptides measured by MTT-assay in hippocampal slices
Table 4. Binding proteins for Αβ 1-42 identified by mass spectrometry in rat brain synaptic plasma membranes (Verdier et al. J Neurochem 94 (3) : 617-28 , 2005)
Claims
1. Peptides or peptidomimetics according to general formula I: X-A1-A2-A3-A4-A5-Y (I) wherein
X is absent or represents: acetyl, propionyl, succinyl group Al is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala, Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, succinyl, Pro, acetyl, 2-amino-adipoic acid, propionyl group;
A2 is absent or represents: Pro, Tic, thiaproline, a-methyl-
Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid,
Glu, Asp, 2-carboxy-piperazine, succinyl, Glp, acetyl, GABA, propionyl group;
A3 is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala, Abu, norvaline, Asp, Glu, Glp, acetyl, succinyl, GABA, propionyl group;
A4 is absent or represents: Pro, Tic, thiaproline, a-methyl- Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid,
Glu, Asp, 2-carboxy-piperazine, succinyl, Glp group;
A5 represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala,
Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, 2- amino-adipoic acid, Pro;
Y is absent or represents: amide, N-methylamide, or N, N- dimethyl-amide;
provided that if A2 is absent than Al is also absent and if A3 is absent than Al and A2 are also absent, and if A4 is absent than Al, A2 and A3 are also absent;
and to their pharmaceutically acceptable salts and esters.
2. Peptides or peptidomimetics according to claim 1, where the peptides or peptidomimetics are selected from peptides with the following sequences: DP-amide (SEQ ID NO 1),
EP-amide (SEQ ID NO 2),
Suc-Pro-amide (SEQ ID NO 3),
Suc-PA-amide (SEQ ID NO 4),
Suc-pa-amide (SEQ ID NO 5),
Glp-Gly (SEQ ID NO 6),
Ac-Glp-G (SEQ ID NO 7),
glp-G (SEQ ID NO 8) ,
Glp-Asp-amide (SEQ ID NO 9),
glp-asp-amide (SEQ ID NO 10),
EPA-amide (SEQ ID NO 11),
Ac-EPA-amide (SEQ ID NO 12),
EPP-amide (SEQ ID NO 13),
ape-amide (SEQ ID NO 14),
Ac-ape-amide (SEQ ID NO 15),
GABA-pe-amide (SEQ ID NO 16),
DPA-amide (SEQ ID NO 17),
EPAP -amide (SEQ ID NO 18),
Ac-EPAP-amide (SEQ ID NO 19),
pape-amide (SEQ ID NO 20),
pppe-amide (SEQ ID NO 21),
Suc-PAPA-amide (SEQ ID NO 22),
Propionyl-PAPA-amide (SEQ ID NO 23),
Iminodiacetyl-PAPA-amide (SEQ ID NO 24),
Propionyl-pape-amide (SEQ ID NO 25),
Propionyl-papq-amide (SEQ ID NO 26),
apap-amide (SEQ ID NO 27),
EPAPA (SEQ ID NO 28) ,
EPPPA (SEQ ID NO 29) ,
APAPE-amide (SEQ ID NO 30),
epapa-amide (SEQ ID NO 31), epppa -amide (SEQ ID NO 32),
apape -amide (SEQ ID NO 33),
apppe -amide (SEQ ID NO 34),
RPAPA -amide (SEQ ID NO 35),
KPAPA -amide (SEQ ID NO 36),
RPPPA -amide (SEQ ID NO 37),
KPPPA-amide (SEQ ID NO 38),
DPAPA-amide (SEQ ID NO 39),
β-Ala-PAPA-amide (SEQ ID NO 40),
E-Sar-APA-amide (SEQ ID NO 41),
EPA-Sar-A-amide (SEQ ID NO 42),
E-Pip-APA-amide (SEQ ID NO 43),
EPA-Pip-A-amide (SEQ ID NO 44),
E-Sar-A-Sar-A-amide (SEQ ID NO 45), apapq (SEQ ID NO 46) ,
apapd-amide (SEQ ID NO 47),
apapn (SEQ ID NO 48) ,
apapq-amide (SEQ ID NO 49),
apapn-amide (SEQ ID NO 50),
apape (SEQ ID NO 51) ,
apGpe-amide (SEQ ID NO 52),
ap-N-Me-ala-pe-amide (SEQ ID NO 53), a-tic-ape-amide (SEQ ID NO 54), apa-tic-e-amide (SEQ ID NO 55), ap-tic-pe-amide (SEQ ID NO 56), a-Sar-ape-amide (SEQ ID NO 57), apa-Sar-e-amide (SEQ ID NO 58), a-pip-ape-amide (SEQ ID NO 59), apa-pip-e-amide (SEQ ID NO 60),
Gpape amide (SEQ ID NO 61),
(N- e-ala) -pape-amide (SEQ ID NO 62), ap-Aib-pe-amide (SEQ ID NO 63),
Aib-pape-amide (SEQ ID NO 64),
APEPA-amide (SEQ ID NO 65),
3. Peptides or peptidomimetics according to claim 2, where the peptides or peptidomimetics are selected from the following sequences :
EPP-amide (SEQ ID NO 13),
ape-amide (SEQ ID NO 14),
GABA-pe-amide (SEQ ID NO 16),
DPA-amide (SEQ ID NO 17),
pppe-amide (SEQ ID NO 21),
EPAPA (SEQ ID NO 28) ,
EPPPA (SEQ ID NO 29) ,
epppa-amide (SEQ ID NO 32),
apapq (SEQ ID NO 46) ,
apapn (SEQ ID NO 48) ,
apape (SEQ ID NO 51) and pharmaceutically acceptable salts and esters thereof.
4. Pharmaceutical preparation, which contains at least one peptide or peptidomimetic of the general formula (I)
wherein
X is absent or represents: acetyl, propionyl, succinyl group Al is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala, Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, succinyl, Pro, acetyl, 2-amino-adipoic acid, propionyl group;
A2 is absent or represents: Pro, Tic, thiaproline, a-methyl- Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid,
Glu, Asp, 2-carboxy-piperazine, succinyl, Glp, acetyl,
GABA, propionyl group;
A3 is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala,
Oi-methyl-Ala, Abu, norvaline, Asp, Glu, Glp, acetyl, succinyl, GABA, propionyl group;
A4 is absent or represents: Pro, Tic, thiaproline, a-methyl-
Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid,
Glu, Asp, 2-carboxy-piperazine, succinyl, Glp group;
A5 represents: Ala, Gly, Aib, Sar, N-methyl-Ala, -methyl-Ala, Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, 2- amino-adipoic acid, Pro;
Y is absent or represents: amide, N-methylamide, or N, N- dimethyl-amide ;
provided that if A2 is absent than Al is also absent and if A3 is absent than Al and A2 are also absent, and if A4 is absent than Al, A2 and A3 are also absent;
and/or contains the pharmaceutically acceptable salt and ester of a peptide according to general formula (I) , and at least one pharmaceutically acceptable additive.
5. Pharmaceutical preparation according to claim 3, characterised by that at least one pharmaceutically acceptable additive is a matrix ensuring controlled active agent release.
6. Pharmaceutical preparation according to claim 3 or 4, characterised by that the peptide according to general formula (I) is selected from peptides or peptidomimetics with the following sequences: EPP-amide (SEQ ID NO 13),
ape-amide (SEQ ID NO 14),
GABA-pe-amide (SEQ ID NO 16),
DPA-amide (SEQ ID NO 17),
pppe-amide (SEQ ID NO 21),
EPAPA (SEQ ID NO 28) ,
EPPPA (SEQ ID NO 29) ,
epppa-amide (SEQ ID NO 32),
apapq (SEQ ID NO 46) ,
apapn (SEQ ID NO 48) ,
apape (SEQ ID NO 51)
and pharmaceutically acceptable salts and esters thereof.
7. The use of peptides or peptidomimetics according to general formula (I)
X-A1-A2-A3-A4-A5-Y (I) wherein
X is absent or represents: acetyl, propionyl, succinyl group Al is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala, Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, succinyl, Pro, acetyl, 2-amino-adipoic acid, propionyl group;
A2 is absent or represents: Pro, Tic, thiaproline, a-methyl- Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid, Glu, Asp, 2-carboxy-piperazine, succinyl, Glp, acetyl, GABA, propionyl group;
A3 is absent or represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala, Abu, norvaline, Asp, Glu, Glp, acetyl, succinyl, GABA, propionyl group;
A4 is absent or represents: Pro, Tic, thiaproline, -methyl- Pro, γ-hidroxy-Pro, Sar, 4-fluoro-Pro, Pip, Nipecotic acid, Glu, Asp, 2-carboxy-piperazine, succinyl, Glp group;
A5 represents: Ala, Gly, Aib, Sar, N-methyl-Ala, a-methyl-Ala, Abu, norvaline, Asp, Glu, iminodiacetic acid, GABA, 2- amino-adipoic acid, Pro,
Y is absent or represents: amide, N-methylamide, or N, N- dimethyl-amide;
provided that if A2 is absent than Al is also absent and if A3 is absent than Al and A2 are also absent, and if A4 is absent than Al, A2 and A3 are also absent;
and their pharmaceutically acceptable salt and ester in the manufacture of a pharmaceutical preparation useful for the prophylaxis or treatment of diseases that can be cured by protection against the detrimental effect of Αβ-peptides.
8. Use according to claim 7, where the disease that can be cured by protection against the detrimental effect of Αβ- peptides is selected from neurodegenerative diseases and type II diabetes mellitus.
9. Use according to claim 7, where the disease that can be cured by protection against the detrimental effect of Αβ- peptides is selected from the following: both familial and late-onset Alzheimer's disease, Parkinson's disease, Down syndrome, type II diabetes mellitus and amyloidosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1600222A HU231182B1 (en) | 2013-05-17 | 2014-05-08 | Small peptide inhibitors of ß-amyloid toxicity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP1300317 | 2013-05-17 | ||
HUP1300317 | 2013-05-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014184596A2 true WO2014184596A2 (en) | 2014-11-20 |
WO2014184596A3 WO2014184596A3 (en) | 2015-04-16 |
Family
ID=51059496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2014/000042 WO2014184596A2 (en) | 2013-05-17 | 2014-05-08 | SMALL PEPTIDE INHIBITORS OF β-AMYLOID TOXICITY |
Country Status (2)
Country | Link |
---|---|
HU (1) | HU231182B1 (en) |
WO (1) | WO2014184596A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106800590A (en) * | 2015-11-25 | 2017-06-06 | 中国科学院过程工程研究所 | Polypeptide and its application of a kind of combination various amyloid protein monomers and aggregation |
US12018096B2 (en) | 2017-09-20 | 2024-06-25 | Councel of Scientific & Industrial Research | Potent peptide inhibitors of protein aggregation |
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100137207A1 (en) | 2000-04-21 | 2010-06-03 | Tufts Medical Center | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5701300A (en) * | 1999-08-09 | 2001-03-05 | Tripep Ab | Protein polymerization inhibitors and methods of use |
GB0503434D0 (en) * | 2005-02-18 | 2005-03-30 | Senexis Ltd | Amyloid-binding peptides, analogues and uses thereof |
EP2089419A2 (en) * | 2006-10-27 | 2009-08-19 | Zapaloid Limited | Inhibition of beta-amyloid aggregation |
-
2014
- 2014-05-08 WO PCT/HU2014/000042 patent/WO2014184596A2/en active Application Filing
- 2014-05-08 HU HU1600222A patent/HU231182B1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100137207A1 (en) | 2000-04-21 | 2010-06-03 | Tufts Medical Center | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same |
Non-Patent Citations (80)
Title |
---|
ABRAMOWSKI ET AL., J NEUROSCI, vol. 32, 2011, pages 1273 - 1283 |
AGUZZI; FALIG, NATURE NEUROSCI., vol. 15, no. 7, 2012, pages 936 - 939 |
AGUZZI; RAJENDRAN, NEURON, vol. 64, 2009, pages 783 - 790 |
AMIJEE; SCOPES, J ALZ DIS, vol. 17, 2009, pages 33 - 47 |
AUER ET AL., PHYSA REV LETT, vol. 101, 2008, pages 258101 |
BAYER; WIRTHS, NERVENARTZ, vol. 79, no. 3, 2010, pages 117 |
BERRIMAN ET AL., PROC NATL ACAD SCI U.S.A., vol. 100, no. 15, 2003, pages 9034 - 8 |
BILLINGS, NEURON, vol. 45, 2005, pages 675 - 688 |
BIOCHEMISTRY, vol. 14, no. 2, 1975 |
BOZSO ET AL., PEPTIDES, vol. 31, 2010, pages 248 - 256 |
BRAAK H.; BRAAK E., NEUROBIOL. AGING, vol. 16, 1995, pages 271 - 278 |
BRAAK; BRAAK, NEUROBIOL AGING, vol. 16, no. 3, 1995, pages 271 - 8 |
BROERSEN ET AL., ALZ. RES THER, vol. 2/12, 2010, pages 1 - 14 |
BROERSEN ET AL., ALZHEIMER'S RES & THERAPY, vol. 2, no. 4, 2010, pages 12 - 14 |
CASAS ET AL., AM J PATHOL, vol. 165, 2004, pages 1289 - 1300 |
CASE ET AL., AMBER 8, 2004 |
CHOU; FASMAN, ANNU REV BIOCHEM, vol. 47, 1978, pages 251 - 276 |
DATKI ET AL., BRAIN RES BULL., vol. 74, no. 1-3, 2007, pages 183 - 7 |
DINTZIS ET AL., PROTEINS, vol. 16, no. 3, 1993, pages 306 - 308 |
DOBSON, TRENDS BIOCHEM SCI., vol. 24, no. 9, 1999, pages 329 - 32 |
EANES; GLENNER, J HISTOCHEM CYTOCHEM, vol. 16, no. 11, 1968, pages 673 - 7 |
EISELE ET AL., SCIENCE, vol. 330, 2010, pages 980 - 982 |
FRIEDHOFF ET AL., BIOCHEMISTRY, vol. 37, no. 28, 1998, pages 10223 - 30 |
FRIEDRICH ET AL., PROC NATL ACAD SCI USA, vol. 107, 2010, pages 1942 - 1947 |
FULOP ET AL., RESEARCH SIGNPOST 37/661, vol. 82, 2009, pages 161 - 188 |
GAJDUSEK, MOL NEUROBIOL, vol. 8, no. 1, 1994, pages 1 - 13 |
GIMÉNEZ-LLORT ET AL., NEUROSCI BIOBEHAV REV, vol. 31, 2007, pages 125 - 147 |
GOEDERT ET AL., CURR OPIN NEUROBIOL, vol. 8, no. 5, 1998, pages 619 - 32 |
GONZALEZ; MONTALBAN ET AL., PLOS PATHOG, vol. 7, 2011, pages E1001277 |
GOURAS ET AL., ACTA NEUROPATHOL, vol. 119, 2010, pages 523 - 541 |
GRIFFITH, NATURE, vol. 215, 1967, pages 1043 - 44 |
HAASS ET AL., NATURE, vol. 359, 1992, pages 322 - 325 |
HARDY; HIGGINS, SCIENCE, vol. 256, 1992, pages 184 - 185 |
HARTMANN, EUR ARCH PSYCHIATRY CLIN NEUROSXCI, vol. 249, 1999, pages 291 - 298 |
HESS ET AL., J. CHEM. THEORY COMPUT., vol. 4, 2008, pages 435 - 447 |
HETÉNYI; VAN DER SPOEL, PROTEIN SCIENCE, vol. 11, 2002, pages 1729 - 1737 |
IQBAL ET AL., ACTA NEUROPATHOL, vol. 109, no. 1, 2009, pages 25 - 312 |
ITTNER; GÖTZ, NATURE REV NEUROSCIENCE, vol. 12, 2011, pages 67 - 72 |
JELINEK, R.: "Lipids and cellular membranes in amyloid diseases", 2011, WILEY, article ZHANG, pages: 143 - 159 |
JUCKER; WALKER, ANN NEUROL, vol. 70, 2011, pages 532 - 540 |
KISILEVSKY ET AL., NAT MED, vol. 1, no. 2, 1995, pages 143 - 148 |
LAFERLA ET AL., NAT REV NEUROSCI, vol. 8, 2007, pages 499 - 509 |
LEVINE, PROTEIN SCI, vol. 2, no. 3, 1993, pages 404 - 10 |
LI ET AL., PROG NEUROBIOL, vol. 83, 2007, pages 131 - 139 |
LUE ET AL., AM J PATHOL, vol. 155, 1999, pages 853 - 862 |
MCLEAN ET AL., ANN NEUROL, vol. 46, 1999, pages 860 - 866 |
MORALES ET AL., MOL PSYCHIATRY, vol. 17, 2012, pages 1347 - 1353 |
MORENO; GONZALEZ; SOTO, SEMIN CELL DEV BIOL, vol. 22, 2011, pages 482 - 487 |
MORRIS ET AL., J. COMPUT. CHEM., vol. 19, 1998, pages 1639 - 1662 |
MUNCH; ROBINSON, J NEURAL TRANSM, vol. 109, no. 708, 2002, pages 1081 - 1087 |
MURAYAMA ET AL., NEUROSCI LETT, vol. 413, 2007, pages 270 - 273 |
NOMENCLATURE OF A-AMINO ACIDS, RECOMMENDATIONS, 1974 |
NUSSBAUM ET AL., NATURE, vol. 485, 2012, pages 651 - 655 |
PATEL; JHAMANDAS, EXPERT REV MOL MED, vol. 14, pages E2 |
PODUSLO ET AL., J NEUROBIOL, vol. 39, no. 3, 2003, pages 371 - 382 |
POLYMENIDOU; CLEVELAND, J EXP MED, vol. 209, 2012, pages 889 - 893 |
PRUSINER, BIOCHEMISTRY, vol. 23, no. 25, 1984, pages 5898 - 906 |
SAA ET AL., J BIOL CHEM, vol. 281, 2006, pages 35245 - 35252 |
SELKOE, J ALZHEIMERS DIS, vol. 3, no. 1, 2001, pages 75 - 80 |
SELKOE, PHYSIOL REV, vol. 81, 2001, pages 741 - 766 |
SHIPTON ET AL., J NEUROSCI, vol. 31, 2011, pages 1688 - 1692 |
SIPE; COHEN, J STRUCT BIOL, vol. 130, no. 2-3, 2000, pages 88 - 98 |
SMALL; DUFF, NEURON, vol. 60, 2008, pages 534 - 542 |
SOTO ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 226, no. 3, 1996, pages 672 - 680 |
SOTO ET AL., TIBS, vol. 31, 2006, pages 150 - 155 |
SOTO ET AL., TINS, vol. 25, 2002, pages 390 - 394 |
SOTO ET AL., TINS, vol. 25, 2002, pages 390394 |
SOTO, TIBS, vol. 36, no. 3, 2010, pages 151 - 8 |
SOTO; SATANI, TREND MOL MED, vol. 17, 2011, pages 14 - 24 |
SRINAVASAN ET AL., J. AM. CHEM. SOC., vol. 120, 1998, pages 9401 - 9409 |
STOHR ET AL., PROC NATL ACAD SCI U S A., vol. 27, 2012, pages 11025 - 30 |
TAKASHIMA, CURR ALZHEIMER RES, vol. 5, no. 6, 2008, pages 591 - 8 |
THATHIAH; DE STROOPER, NAT REV NEUROSCI, vol. 12, no. 2, 2011, pages 73 - 87 |
TOMIYAMA, J NEUROSCI, vol. 30, 2010, pages 4845 - 4856 |
TOMPA, FEBS J, vol. 276, no. 19, 2009, pages 5406 - 15 |
VERDIER ET AL., J NEUROCHEM, vol. 94, 2005, pages 617 - 628 |
VERDIER ET AL., J. NEUROCHEM., vol. 94, 2005, pages 617 - 28 |
VERDIER; PENKE, CURR PROT &.PEPTIDE SCIENCE, 2004, pages 19 - 31 |
WOOD ET AL., J BIOL CHEM, vol. 271, no. 8, 1996, pages 4086 - 4092 |
XU ET AL., PROG NEUROBIOL, vol. 97, 2012, pages 1 - 13 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106800590A (en) * | 2015-11-25 | 2017-06-06 | 中国科学院过程工程研究所 | Polypeptide and its application of a kind of combination various amyloid protein monomers and aggregation |
CN106800590B (en) * | 2015-11-25 | 2021-04-09 | 杭州智鹤丹谷生物医药有限公司 | Polypeptide combining multiple amyloid protein monomers and aggregates and application thereof |
US12018096B2 (en) | 2017-09-20 | 2024-06-25 | Councel of Scientific & Industrial Research | Potent peptide inhibitors of protein aggregation |
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
Also Published As
Publication number | Publication date |
---|---|
HU231182B1 (en) | 2021-08-30 |
HUP1600222A2 (en) | 2017-06-28 |
WO2014184596A3 (en) | 2015-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6381737B2 (en) | Methods and compositions for preventing or treating eye diseases | |
US10987400B2 (en) | Methods for the treatment of glaucoma and age-related macular degeneration by a peptide D-TRP-AIB | |
CA2698766C (en) | Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission | |
US9060991B2 (en) | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission | |
Parsons et al. | MRZ-99030–A novel modulator of Aβ aggregation: I–mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD) | |
US9717772B2 (en) | Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases | |
WO2014184596A2 (en) | SMALL PEPTIDE INHIBITORS OF β-AMYLOID TOXICITY | |
US20050090449A1 (en) | Novel statine derivatives for the treatment of Alzheimer's disease | |
EP4137502A1 (en) | Vipr2 antagonist peptide | |
KR20220110278A (en) | Peptide compositions and methods for treating tauopathy | |
WO2002092115A2 (en) | Method of preventing cell death using segments of neural thread proteins | |
EA016040B1 (en) | Dlhw neuroprotective compound and uses thereof | |
US11970521B2 (en) | Neuroprotective beta amyloid core peptides and peptidomimetic derivatives | |
WO2015054005A1 (en) | Compositions and methods for treatment of bdnf-related conditions | |
US20230374067A1 (en) | Novel peptoids and use thereof for preventing or treating chronic pain | |
CA3240607A1 (en) | Composition for treating macular degeneration comprising novel peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14734545 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14734545 Country of ref document: EP Kind code of ref document: A2 |